

Curriculum Vitae
Sangeet Ghai
MD, DNB, FRCR

A. Date Curriculum Vitae is Prepared: April 2024

B. Biographical Information

Primary Office Division of Abdominal Imaging
 Joint Department of Medical Imaging
 University Health Network – Toronto General Hospital
 585 University Avenue, 1C544
 Toronto, Ontario, Canada M5G 2N2
Telephone: (416) 340-4696
Fax: (416) 340-3900
E-mail: sangeet.ghai@uhn.ca

1. EDUCATION

Degrees

1986 – 1992 MBBS, Assam Medical College, Dibrugarh, India
1995 – 1998 MD (Radio-diagnosis), Govt Medical College, Amritsar, India
1999 – 2002 Senior Residency, All India Institute of Medical Sciences, Delhi, India

Postgraduate, Research and Specialty Training

2003 Jul – 2004 Jun Vascular & Interventional Radiology, Clinical Fellowship, University Health Network –
 Mount Sinai Hospital, University of Toronto, Toronto, Ontario
2002 Jul – 2003 Jun Abdominal Imaging, Clinical Fellowship, University Health Network – Mount Sinai,
 Hospital, University of Toronto, Toronto, Ontario
1999 Jan – 2002 Jan Senior Residency, All India Institute of Medical Sciences, New Delhi, India
1995 Jul – 1998 Oct Radiology Residency, Government Medical College, Amritsar, India

Qualifications, Certifications and Licenses

2006 Dec Licensure, College of Physicians & Surgeons of Ontario, Canada, License #: 78106
2006 Nov Fellow, Clinical Radiology, Royal College of Radiologists
2004 Apr Licensure, General Medical Council, United Kingdom, License #: 6095489
2002 Jan Licensure (Permanent – Additional Qualification), Medical Council of India, India,
 License #: 2182
1999 Dec Diplomate, Radio-Diagnosis, National Board (DNB), India
1998 Nov Certification, Radio-Diagnosis, MD, India
1991 Oct Licensure (permanent), Medical Council of India, India, License #: 10911

2. EMPLOYMENT

Current Appointments

2007 Jan – present	Staff Radiologist, Division of Abdominal Imaging, Department of Medical Imaging, University Health Network – Mount Sinai Hospital, Toronto, Ontario
2007 Jan – present	Staff Radiologist, Division of Abdominal Imaging, Department of Medical Imaging, Toronto General Hospital, Toronto, Ontario
2007 Jan – 2015	Assistant Professor, Department of Medical Imaging, University of Toronto, Toronto, Ontario
2015 July – present	Associate Professor, Department of Medical Imaging, University of Toronto, Toronto, Ontario
2018 Feb – present	Director of Research, Joint Department of Medical Imaging, University Health Network
2021 July – present	Professor, Department of Medical Imaging, University of Toronto, Toronto, Ontario

Previous Appointments

2004 Jul – 2006 Dec	Consultant Radiologist & College Tutor, University Hospital of North Staffordshire NHS Trust, Keele University, Stoke-on-Trent, United Kingdom
---------------------	--

3. HONOURS AND CAREER AWARDS

Distinctions and Research Awards

INTERNATIONAL

Received

2013	Certificate of Merit , Radiological Society of North America. (Distinction)
2006	Awarded Fellowship without Examination , Royal College of Radiologists, United Kingdom. (Credential)
2006	Clinical Excellence Award , UHNS NHS Trust, United Kingdom. (Distinction)
2005	Certificate of Merit , Radiological Society of North America. (Distinction)
2004	2004 Roentgen Resident/Fellow Research Award , Radiological Society of North America. (Research Award)
2004	Best Preferred Paper , 6th Asia-Pacific Congress of Vascular & Interventional Radiology, New Delhi, India. (Distinction)
2003	Certificate of Merit , Radiological Society of North America. (Distinction)
2001	Best Preferred Paper , Millennium Imaging Conference, Delhi, India. (Distinction)

LOCAL

Received

1998	Best Postgraduate Student , GND Univ, Amritsar, India. (Distinction)
1988	Honors in Biochemistry . (Distinction) 1st Professional Medical Exam.
1987	Honors in Chemistry . (Distinction) 1st Professional Medical Exam.
1986	Honors in Chemistry , Class XII Board Examination. (Distinction)

4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

Professional Associations

2007 – 2011	Member , American Roentgen Ray Society (ARRS), Membership #: 701003
2013 – present	Member , American Urological Association (AUA), Membership #: 00850760
2007 – 2014	Member , Canadian Medical Association (CMA)
2004 – 2008	Member , European Society of Gastrointestinal and Abdominal Radiology (ESGAR), Membership #: 103511
2014 – 2018	Canadian Lead for ESUR , European Society of Urogenital Radiology (ESUR)
2012 – present	Lifetime Member , Indian Association of Radiology and Imaging (IARI)
2013 – 2015	Member , International Society of Magnetic Resonance in Medicine (ISMRM), Membership #: 49770
2007 – 2019	Member , Ontario Association of Radiologists (OAR)
2007 – present	Member , Ontario Medical Association (OMA), Membership #: 0852442
2004 – 2017	Member , Radiological Society of North America (RSNA), Membership #: 00333307
2006 – 2017	Member , Royal College of Radiologists, United Kingdom, Membership #: 310298
2012 – 2021	Member , Society of Abdominal Radiology (SAR), Membership #: 27201130

Administrative Activities

PROVINCIAL / REGIONAL

Cancer Care Ontario (CCO)

Expert panel - 2017 Thyroid Cancer Diagnosis and Treatment Pathway Maps

Expert panel – 2019 updated Thyroid Cancer Diagnosis and Treatment Pathway Maps

Expert panel on developing clinical practice guidelines for the new CCO guideline, #27-2, MRI in the diagnosis and staging of prostate cancer.

External review of CCO's Program in Evidence-based Care (PEBC) guideline on active surveillance for the management of localized prostate cancer

External review of CCO's Program in Evidence-based Care (PEBC) guideline on multiparametric MRI in the diagnosis of clinically significant prostate cancer.

LOCAL

University Health Network/ Mount Sinai Hospital/ Women's College Hospital

2007 Jul – present **Member**, Toronto, Ontario, Canada. Peri-procedural hemostasis policy working group.

Member, Toronto, Ontario, Canada. BioBank working committee.

Sangeet GHAI

2011 Aug – present **Lead Clinician**, Toronto, Ontario, Canada. Responsible for setting up and overseeing the functioning of the Thyroid Biopsy Specialist position at UHN, the first of its kind in North America.

2018 Mar – present **Deputy Chief (Research)**, Joint Department of Medical Imaging, UHN

2018 July – present **Director**, Prostate Centre, Princess Margaret Cancer Centre

2009 Jan – present **Director**, Biopsy Centre, TGH, Responsible for directing and overseeing the daily functioning of the Biopsy Centre.

Peer Review Activities

MANUSCRIPT REVIEWS

Reviewer

2015 – present Radiology
2015 – present Radiographics
2015 – present Journal of Urology
2014 – present Nature
2014 – present Abdominal Imaging
2014 – present Head and Neck
2014 – present Journal of Vascular and Interventional Radiology
2014 – present Urologic Oncology: Seminars and Original Investigations
2013 – present International Journal of Computer Assisted Radiology and Surgery
2007 – present Yonsei Medical Journal
2020 – present Journal of Magnetic Resonance Imaging
2021 – present Frontiers in Oncology
2021 – present Thyroid

C. Research Funding / Awards

Grants Awarded

2021 Apr – 2024 Apr	Principle Investigator. Use of Artificial Intelligence Algorithms in Risk Stratification for Management of Thyroid Neoplasms. [JDMI AI Centre: Inaugural Call for Translational Projects] Total Funding: \$200, 000 The objective of the study is to establish implementation of AI algorithms for: a) risk stratification of thyroid nodules for biopsy b) predicting small, low risk thyroid cancer disease progression under active surveillance.
2020 Aug – 2025 July	Principal Investigator. Advancing MRI guided focal laser ablation (MRgFLA) of prostate cancer. Total Funding: 1,000,000 CAD. [PMH Foundation] This study will evaluate - Development of treatment Optimization Software for MrgFLA - Use of SpaceOAR to dissect space between Dennonvillier’s fascia and rectum in MRgFLA

	<ul style="list-style-type: none"> - Role of PSMA PET in defining tumor margins for focal treatment - The first in human trials of MRgFLA in presence of porphysomes to localize and destroy localized prostate cancer
2021 Sep - 2023 Dec	<p>Principal Investigator: Focal laser ablation under micro-ultrasound guidance. Phase 1 safety and feasibility study. 7 patients with localized GG2 disease will be treated by FLA under Micro-Ultrasound. All patients will have MRI 1 week following therapy followed by MRI and biopsy at 6 months. Exact Imaging [Industrial Grants]. Total Funding: \$200,000</p>
2019 Apr - 2021 Mar	<p>Principal Investigator: Comparison of Micro-ultrasound targeted biopsy to mpMRI of Prostate for detection of clinically significant prostate cancer. MSH-UHN AMO Innovation Fund. This project will compare micro-ultrasound imaging modality to the current gold-standard imaging for prostate cancer, mpMRI. By applying both modalities to the same patients, we will provide a direct comparison of their screening abilities in terms of sensitivity, specificity, negative predictive value and positive predictive value. Total Funding: \$ 183,322.91</p>
2018 Mar - 2021 Jun	<p>Principal Investigator. 'MRI guided focal laser ablation of prostate cancer: Phase II study' as part of the apply phase of Smart Prostate Imaging and Intervention study (SPIRIT). Ontario Institute for Cancer Research (OICR). PI: Bauman, Glen; Fenster, Aaron. Total 2,400,000 CAD. [Grants] Budget for Apply phase \$546,910 CAD (PI – Sangeet Ghai). This study will evaluate the proportion of patients with organ-confined low and intermediate risk prostate cancer undergoing focal MRgFLA prostate treatment that will be free of clinically significant PCa which requires definitive treatment at 2 years after completion of their treatment. The study will also evaluate treatment effect on patients' Quality of Life using validated questionnaires at different time points following treatment. Accuracy of intrinsic Photoacoustic Imaging (i-PAI) of post treatment coagulation zone will also be assessed as a secondary objective</p>
2017 July - 2021 Jun	<p>Principal Investigator. Focal MR-guided focused ultrasound treatment of localized intermediate-risk prostate cancer: Phase II study. InSightec-TxSonics Inc. Collaborators: Finelli A, Kucharczyk W, van der Kwast T, McCluskey S. Total Funding 1,600,000 CAD. [Industrial Grants] The goal of this study is to evaluate the safety and effectiveness of focal MRgFUS treatment of low risk prostate cancer.</p>
2019 Jan – 2023 Dec	<p>Co-Investigator & Imaging Lead: Active surveillance or surgery for primary management of very low risk papillary thyroid cancer: How often are the long-term disease management goals achieved? CIHR/IRSC Project Grant. Total Funding: \$1,013,635 [Grants] PI: Annie Sawka</p>
2017 Jul – 2023 Jun	<p>Co-Investigator: Porphysome Nanoparticle Enabled Image Guided Cancer Interventions. Terry Fox New Frontiers Program Project Grant. This program directs towards the development, optimization and translation into clinic a novel class of nanoparticles, porphysomes, to address specific unmet needs in cancer care. Project 1 focuses on the design and fabrication of novel photoacoustic instruments for prostate, thyroid and esophagus cancer imaging. Project 2 is about preclinical optimization followed by first clinical trials of photothermal therapy in the presence of porphysomes.</p>

	<p>Project 3 is to localize and destroy thyroid cancer nodules by photodynamic therapy using the unique porphyrins as photosensitizers. The core (porphyrin foundry) is expected to provide a variety of porphyrins, including new “smart” variants, optimized for the proposed clinical applications.</p> <p>Total Funding: \$6,616,301 PI: Gang Zheng</p>
2016 Jun – 2018 Dec	<p>Co-Investigator & Imaging Lead: Active Surveillance for Low Risk Papillary Thyroid Cancer (REB #15-8942). Co-PIs: D Goldstein (ENT surgeon) & A Sawka (Endocrinologist) PMH foundation funding</p>
2016 Jul – 2019 Jun	<p>Site Co-Principal Investigator (A Finelli & S Ghai). A randomized controlled trial of magnetic resonance imaging targeted biopsy compared to standard trans-rectal ultrasound guided biopsy for the diagnosis of prostate cancer in men without prior biopsy. Prostate Evaluation for Clinically Important disease: MRI vs Standard Evaluation procedures. (PRECISE). A phase III multi-centre open-label randomized controlled trial of multi-parametric magnetic resonance imaging (MRI)-targeted biopsy compared to systematic trans-rectal ultrasound (TRUS) guided biopsy for the diagnosis of prostate cancer in biopsy naive men. The primary objective is to determine whether the proportion of men with clinically significant cancer (Gleason > 7) detected by MRI +/-targeted biopsy is no less than systematic TRUS guided biopsy in all subjects. OICR & PCC (Prostate Cancer Canada) Funded. Total funding \$3,000,000 PI: L Klotz.</p>
2016 Oct – 2020 Dec	<p>Co-Investigator. Open-label clinical study to assess the safety and adequacy of effectiveness of the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI) for the treatment of recurrent prostate cancer. Total Funding: \$28,312 / patient, for a total of 12 patients. PI: Neil Fleshner</p>
2016 Jan – 2016 Dec	<p>Co-Investigator. Prostate Biopsy Avoidance Using Combination PCA3 and Multiparametric Magnetic Resonance Scanning in Selected Patient Cohorts. Astellas Prostate Cancer Innovation Fund. Total funding \$50,000. PI: Neil Fleshner</p>
2013 Jul - 2016 Dec	<p>Principal Investigator. Multi-centre trial (5 sites) of high resolution transrectal ultrasound versus standard low resolution transrectal ultrasound for the identification of clinically significant prostate cancer. The primary objective of this study is to demonstrate that ultra high resolution (UHR)-TRUS is superior to conventional low resolution (LR)- TRUS in guiding systematic (standard, random, extended sextant) plus image-guided prostate biopsies among men without known prostate cancer with an indication for prostate biopsy. Total Funding: 218,280 CAD. [Imagistx Inc., Industrial Grants] PI: Pavlovich, Christian</p>
2013 Jul - 2015 Dec	<p>Principal Investigator. Focal MR-guided focused ultrasound treatment of localized low-risk prostate cancer: feasibility study. Phase 1 study. Collaborators: Trachtenberg J, Kucharczyk W, Haider M, van der Kwast T, McCluskey S. The goal of this study is developing preliminary data to evaluate the safety and preliminary effectiveness of focal MRgFUS treatment of low risk prostate cancer Total Funding: 250,000 CAD</p>

	[InSightec-TxSonics Inc. Industrial Grants]
2013 Jul - 2015 May	<p>Co-Principal Investigator. MRI targeted focal laser thermal therapy of prostate cancer. PMH Foundation, OICR, Terry Fox Grant.</p> <p>The main objective of this study is to evaluate the safety and feasibility of MRI guided focal prostate cancer laser ablation. This is a single centre, open label study in which 60 males, ages 40-80 with biopsy confirmed early clinical stage prostate cancer (T1c or T2a) and identifiable lesion on endorectal dynamic gadolinium enhanced MRI, with a PSA of < 15 mg/ml, who have not yet undergone pelvic radiation or hormonal deprivation therapy.</p> <p>PI: Trachtenberg, John.</p>
2014 Jul - 2017 Jun	<p>Co-Investigator. Procedures to monitor changes in tissue properties. Terry Fox Foundation (The).</p> <p>To develop alternative methods of monitoring the photothermal lesion in focal photothermal treatment of the index tumor in low/intermediate-risk prostate cancer, using either trans-rectal photoacoustic imaging (PAI) or trans-rectal diffuse optical tomography (DOT). Both probes use optical fibers to deliver light to the prostate. PAI uses short-pulse laser light to generate ultrasound waves in the prostate that are used to generate the images, while DOT generates purely optical images. In both cases the changes in the tissue light absorption and/or scattering that occur due to tissue coagulation will be used to monitor the photothermal lesion development. Additionally, in the case of PAI all-organic nanoparticles may be used to enhance the tumor contrast and to provide temperature sensitivity. These advances will accelerate the adoption and widespread, cost-effective dissemination of this minimally invasive approach into clinical practice, by improving its effectiveness and safety and by allowing treatment to be given without the need for cumbersome and expensive on-line MRI monitoring.</p> <p>PI: Wilson, Brian.</p> <p>Total Funding: \$2,100,000. [Grants].</p>
2015 Mar – 2017 Jun	<p>Co-Investigator. Clinical Trial for ProxiScan - Detection and localization of carcinoma using high resolution transrectal imaging (TRI) – Proof of concept study.</p> <p>Primary Objective: To determine the feasibility of a Transrectal Scintigraphic Detector (ProxiScan) to detect and localize prostate specific membrane antigen (ProstaScint) radiotracer uptake in men with biochemical failure (BCF) following radical prostatectomy (RP), as a surrogate marker of local tumour recurrence. Secondary Objective: To determine the feasibility of a Transrectal Scintigraphic Detector (ProxiScan™) to detect and localize prostate specific membrane antigen (ProstaScint) radiotracer uptake in men with multiple negative prostate biopsies.</p> <p>PI: Antonio Finelli.</p> <p>Total Funding: \$508,794.90</p>
2014 Apr - 2019 Feb	<p>Co-Investigator. NCI Experimental Therapeutics-Clinical Trials Network with Phase I Emphasis (ET-CTN) (UM1). Princess Margaret Phase 1 Consortium (PMP1C). PI: Siu, Lillian; Sullivan D, Hotte S, Chi K. 1,756,985 USD. [Grants]</p> <p>1) To conduct innovative, coordinated, efficient, regulatory-compliant and high impact early phase clinical trials in experimental therapeutics, which are designed to address important questions that do not duplicate research supported by the pharmaceutical industry or other sources;</p> <p>2) To adopt a team science interdisciplinary approach with internal and external collaborations to enhance the optimal evaluation of novel anticancer agents alone or in combination;</p> <p>3) To accelerate biomarker development and correlative sciences research through comprehensive molecular characterization of tumors obtained from patients enrolled on ET-CTN trials to elucidate mechanism of action, as well as predictors of therapeutic response and/or resistance; and</p> <p>4) To emphasize training and education to foster career development of junior investigators. PMP1C is committed to actively lead ET-CTN early phase trials as well as to contribute as a meaningful partner</p>

	to ET-CTN trials led by other Consortia. With a strong Leadership that is supported by the Steering Committee, Translational Research, Clinical Research and Operational Cores, PMP1C embraces a team science approach to conduct the most relevant early phase clinical trials of novel agents alone or in combination. All patients enrolled by the PMP1C will undergo comprehensive molecular characterization using advanced genotyping or targeted sequencing approaches to help identify drivers of drug sensitivity or resistance. This data, along with pharmacological, immune function, and quantitative imaging data, will enable the most optimal biological correlation with clinical outcome. Leveraging resources from other sources including institutional support, the PMP1C will further advance whole exome/whole genome next generation sequencing technologies within the timeframe of this award in the next 5 years.
2013 Jul - 2016 Jun	Co-Investigator. XENO-METPANC Study. PI: Dhani, Neesha; Moore, Malcolm. [Grants] To determine feasibility of establishing patient-derived xenografts from core biopsies of liver metastases of pancreatic cancer and to optimize assays for evaluation of peripheral biomarkers of advanced pancreatic cancer.
2013 Jul - 2016 Jun	Co-Investigator. A phase II study on the toxicity and efficacy of a normal tissue tolerance adapted, 5 fraction stereotactic body radiation therapy (SBRT) regimen, for extra-cranial oligometastases. PI: Wong, Rebecca. [Grants]
2013 Jul - 2016 Jun	Collaborator. Novel window of opportunity trial to evaluate the impact of statins to oppose prostate cancer (Win-STOPca). PI: Fleshner, Neil; Penn, Linda. [Grants] This phase II clinical trial will conduct a perioperative 'window' trial, treating prostate cancer patients with a cholesterol lowering dose of statins (fluvastatin) to evaluate the response of intermediate/high-grade prostate cancer patients to lipophilic statins. MRI utility to evaluate impact of statins will be assessed. The study will prospectively investigate the changes of ADC values, T2-relaxation and the vascular biomarker Ktrans, in prostate cancers before and 6-10 weeks after administering statins at 3T using a phased-array coil coupled to an endorectal coil, and will explore the endogenous contrast mechanisms (ADC; T2, Ktrans) as quantitative early biomarkers of prostate cancer exposed to statins, in this cohort of patients with intermediate–high risk PCa. Total Funding Ontario Cancer Institute (The) \$521,404
2013 Jul - 2016 Jun	Co-Investigator. PROPS: PET/MRI pre-radiotherapy for post-prostatectomy salvage. Movember. [Grants] Non-randomized prospective multi-center trial to characterize the incremental benefit of secondary staging with 18-Fluorocholine PET and whole body MRI in men being considered for salvage radiotherapy for suspected isolated local recurrence post prostatectomy. PI: Metser, Ur. 200,000 CAD.
2013 Jul - 2016 Jun	Co-Investigator. A feasibility study of genomic profiling methods and timing of sample collection to evaluate clonal evolution and tumor heterogeneity (MATCH Study). Princess Margaret Hospital. Drug Development. PI: Siu, Lillian; Bedard, Phil. [Grants] To determine concordance of genomic analyses between archival samples and fresh core needle biopsy (CNB) samples and fresh fine needle biopsy (FNB) samples. Specifically, this includes determining concordance between samples at different time points and concordance between different sites, namely metastases, sites that are progressing and the primary site.
2012 Jul - 2015 Jun	Co-Investigator. ASIST trial (Active Surveillance Magnetic Resonance Imaging Study). Ontario Institute for Cancer Research (OICR). PI: Klotz, Lawrence. Collaborators: Haider M, Loblaw A (Co-Principal Investigators). 2,700,000 CAD. [Grants] This is a multi-center, prospective, randomized phase III trial of definitive

	treatment versus active surveillance and selective intervention in patients with previously untreated, favourable risk prostate cancer at diagnosis.
2011 Jul - 2016 Jun	Co-Investigator. Personalized medicine with targeted and genome wide sequencing. Cancer Care Ontario. Applied Cancer Research Unit (ACRU) award. PI: Neel, Benjamin; Siu, Lillian. Collaborators: Onetto N (Core A), Ghai S , Murphy K, Haider M, Jaffray D (Core B), Shaw P, Asa S, Tsao M-S (Core C), Kamel-Reid S, McPherson J (Core D), Stein L, Jurisica I (Core E), Moore M, Oza A, Siu L, Shepherd F, Leighl N, Liu G, Chen E, Hedley D, Tsao M-S, Bedard P, Minden M, Stambolic V, Wouters B, Reedijk M, Liu F-F, Bristow R, Hotte S, Goss G, Winquist E (Core F). 1,182,500 CAD. [Grants] The main goals of this proposal are: 1) to establish a rapid, efficient and integrated molecular characterization Genomics Research Unit (GRU) that enables quality-assured genomic evaluations to be performed in cancer patients enrolled under GRU research projects, 2) to develop a well-annotated database encompassing genomic and clinical information from cancer patients enrolled under GRU research projects, 3) to mount at least two GRU research projects during the grant period. These projects will have various sub-aims including: i) demonstration of feasibility of genomic sequencing in the clinical setting; ii) development of disease-specific genomic panels; and iii) proof-of-concept evaluation of prognostic or predictive values of specific genomic biomarkers in selected subgroups of cancers.
2010 Sep - 2014 Aug	Co-Investigator. Translational Research Team Member for High Impact Clinical Trial (HICT) Program. Ontario Institute for Cancer Research. PI: Oza, Amit. Collaborators: Ghai S , Haider M, Milosevic M, Tsao M-S, Chen E, Kamel-Reid S, Shaw P, Boerner S. 1,000,000 CAD. [Grants] Overall program goals are to support resources that will develop streamlined process for conducting clinical trials. This includes building capacity to scale up tissue based specimen processing and pharmacokinetic studies. In future this will include integrating genomics, pharmacokinetic and functional imaging in real time.
2010 Jul-2013 Jun	Semen proteomics to identify novel prostate cancer biomarkers. Canadian Cancer Society Research Institute (CCSRI). PI: Jarvi K. Collaborators: Briollais L, Grober E, Ghai S , Lo K, Margolis M, Mullen B, O'Malley M, Tannenbaum D, Toi A, van der Kwast T, Diamandis E, Finelli A, Zlotta A. Total Funding: \$413,853 CAD.

D. Publications

1. PEER-REVIEWED PUBLICATIONS

Submitted publications (under review)

1. **Ghai S**, Klotz L, Pond GR, Kebabdjian M, Downes MR, Belanger EC, Moussa M, van der Kwast TH. Detection of Cribriform and Intraductal Carcinoma Morphology Prostate Cancer on MRI - Results from a Phase 3 Randomized Clinical Trial'. **Principal Author.** Revisions submitted to *Radiology*.
2. **Ghai S**, Finelli A, Corr K, Lajkoosz K, McCluskey S, Chan R, Gertner M, van der Kwast TH, Incze PF, Zlotta AR, Kucharczyk W, Perlis N. MR guided focused ultrasound focal therapy (MRgFUS) for intermediate risk prostate cancer –phase II study. **Principal Author.** Revisions submitted to *Radiology*

Journal Articles

1. **Ghai S**, Klotz L, Pond GR, Kebabdjian M, Downes MR, Belanger EC, Moussa M, van der Kwast TH. Detection of Cribriform and Intraductal Carcinoma Morphology Prostate Cancer on MRI - Results from a Phase 3 Randomized Clinical Trial'. **Principal Author**. Revisions submitted to *Radiology* [In Press]
2. **Ghai S**, Finelli A, Corr K, Lajkoosz K, McCluskey S, Chan R, Gertner M, van der Kwast TH, Incze PF, Zlotta AR, Kucharczyk W, Perlis N. MR guided focused ultrasound focal therapy (MRgFUS) for intermediate risk prostate cancer –phase II study. Principal Author. *Radiology* 2024 Mar;310(3):e231473. doi: 10.1148/radiol.231473.
3. Dias AB, Chang SD, Fennessy FM, Ghafoor S, **Ghai S**, Panebianco V, Purysko AS, Giganti F. New Prostate MRI Scoring Systems (PI-QUAL, PRECISE, PI-RR, and PI-FAB): *AJR* Expert Panel Narrative Review. *AJR Am J Roentgenol*. 2024 Apr 3. doi: 10.2214/AJR.24.30956. Online ahead of print.
4. Sawka AM, **Ghai S**, Rotstein L, Irish JC, Pasternak JD, Monteiro E, Chung J, Zahedi A, Su J, Xu W, Jones JM, Gafni A, Baxter NN, Goldstein DP. Decision Regret Following the Choice of Surgery or Active Surveillance for Small, Low-Risk Papillary Thyroid Cancer: A Prospective Cohort Study. *Thyroid*. 2024 Apr 8. doi: 10.1089/thy.2023.0634. Online ahead of print.
5. Abreu-Gomez J, Haider M, **Ghai S**. Re: Francesco Giganti, Louise Dickinson, Clement Orczyk, et al. Prostate Imaging After Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. *Eur Urol Oncol*. 2024 Feb;7(1):169-170. doi: 10.1016/j.euo.2023.07.015. Epub 2023 Aug 22.
6. Fleming H, Talbot N, Dias AB, Corr K, Haider MA, **Ghai S**. Inter-reader agreement of the PIQUAL (Prostate MRI Image Quality Score). **Senior Responsible Author**. *Eur J Radiol*. 2023 Nov;168:111091. doi: 10.1016/j.ejrad.2023.111091. Epub 2023 Sep 9.
7. Klotz L, Chin J, Black PC, Finelli A, Anidjar M, Machado A, Levanthal M, **Ghai S**, Chang SD, Patel C, Kassam Z, Loblaw A, Kebabdjian M, Pond G, Haider MA. Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE). *Eur Urol Oncol* 2023 Oct 12:S2588-9311(23)00204-3. [Institutional lead in multi-center trial].
8. Dias AB*, **Ghai S***, Ortega C, Mirshahvalad A, Perlis N, Berlin A, Avery L, Veit-Haibach P, van der Kwast TH, Metser U. Impact of 18F-DCFPyL PET/MRI in Selecting Men with Low/Intermediate-Risk Prostate Cancer for Focal Ablative Therapies. **Co-Principal Author**. *Clin Nucl Med*. 2023 Oct 1;48(10):e462-e467
9. Alaboussi M, **Ghai S**. MR-guided ultrasound ablation for prostate cancer - A contemporary review of performance. *Frontiers Oncol*. 2023 Jan 4;12:1069518. doi: 10.3389/fonc.2022.1069518. **Senior Responsible Author** [Review]
10. Abreu-Gomez J, Dias AB, **Ghai S**. PI-RR: The Prostate Imaging for Recurrence Reporting System for MRI Assessment of Local Prostate Cancer Recurrence After Radiation Therapy or Radical Prostatectomy-A Review. *AJR Am J Roentgenology*. 2023 Jun;220(6):852-861. **Senior Responsible Author**. [Invited Review].
11. Dias AB, **Ghai S**. Micro-Ultrasound: Current Role in Prostate Cancer Diagnosis and Future Possibilities. *Cancers (Basel)* 2023 Feb 17;15(4):1280. **Senior Responsible Author** [Systematic Review].

12. Sawka AM, **Ghai S**, Rotstein L, Irish JC, Pasternak JD, Gullane PJ, Monteiro E, Zahedi A, Gooden E, Eskander A, Chung J, Devon K, Su J, Xu W, Jones JM, Gafni A, Baxter NN, Goldstein DP; Canadian Thyroid Cancer Active Surveillance Study Group (Greater Toronto Area). Gender differences in fears related to low-risk papillary thyroid cancer and its treatment. *JAMA Otolaryngol Head Neck Surg*. 2023 Jul 6:e231642. **[Radiology lead, co-author]**
13. Alaboussi M, **Ghai S**, Haider MA. Magnetic Resonance Imaging-guided Minimally Invasive Focal Therapies for Prostate Cancer: Research in Practice. **Co-SRA** [Radiology, In Press]
14. Dias AB, **Ghai S**. Prostate Cancer Diagnosis with Micro-Ultrasound: what we know now and new horizons. *Radiological Clinics of North America*. July 2023. **Senior Responsible Author** [In Press, Review article]
15. Basso Dias A, Mirshahvalad SA, Ortega C, Perlis N, Berlin A, van der Kwast T, **Ghai S**, Jhaveri K, Metser U, Haider M, Avery L, Veit-Haibach P. The role of [¹⁸F]-DCFPyL PET/MRI radiomics for pathological grade group prediction in prostate cancer. *Eur J Nucl Med Mol Imaging*. 2023 Jun;50(7):2167-2176. **Co-author** [Original Article].
16. Abreu-Gomez J, Haider MA, **Ghai S**. Letter to the Editor re: Prostate Imaging After Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. *Eur Urol Oncol*. In press. **Senior Responsible Author**
17. Westphalen AC, Raman S, Schade GR, Ghanouni P, **Ghai S**, Napoli A, Mishal ML, Vidal J, Sundaram K, Abreu A, Arora S. Therapeutic Ultrasound Applications for The Abdomen And Pelvis" *RadioGraphics* 2022 Oct;42(6):E182-E183. **Co-author**
18. **Ghai S**, Perlis N. Beyond the *AJR*: MRI-Guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer. *AJR Am J Roentgenol* 2023 Apr;220(4):610. **Principal Author**.
19. Callejas MF, Klein EA, Truong M, Thomas L, McKenney JK, **Ghai S**. Detection of Clinically Significant Index Prostate Cancer Using Micro-ultrasound: Correlation With Radical Prostatectomy. *Urology*. 2022 Nov;169:150-155. **Senior Responsible Author** [Original Article].
20. **Ghai S**, Perlis N, Atallah C, Jokhu S, Corr K, Lajkosz K, Incze PF, Zlotta AR, Jain U, Fleming H, Finelli A, van der Kwast TH*, Haider MA *. Comparison of Micro-US and Multiparametric MRI for Prostate Cancer Detection in Biopsy-Naive Men. *Radiology* 2022 Nov;305(2):390-398. **Principal Author** [Original Article].
21. Perlis N, Finelli A, Lovas M, Lund A, Di Meo A, Lajkosz K, Berlin A, Papadakos J, **Ghai S**, Deniffel D, Meng E, Wiljer D, Alibhai S, Bakas V, Badzynski A, Lee O, Cafazzo J, Haider MA. Exploring the value of using patient-oriented MRI reports in clinical practice - a pilot study. *Support Care Cancer*. 2022 Aug;30(8):6877. **Co-Author** [Original Article].
22. Deniffel D, Perlis N, **Ghai S**, Girgis S, Healy GM, Fleshner N, Hamilton R, Kulkarni G, Toi A, van der Kwast T, Zlotta A, Finelli A, Haider MA. Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. *Eur Radiol*. 2022 May 4. **Co-Author** [Original Article].
23. Sawka AM, **Ghai S**, Rotstein L, Irish JC, Pasternak JD, Gullane PJ, Monteiro E, Gooden E, Brown DH, Eskander A, Zahedi A, Chung J, Su J, Xu W, Ihekire O, Jones JM, Gafni A, Baxter NN, Goldstein DP; Canadian Active Surveillance Study Group (Greater Toronto Area). A Quantitative Analysis Examining Patients' Choice of Active Surveillance or Surgery for Managing Low-Risk Papillary Thyroid Cancer. *Thyroid*. 2022 Mar;32(3):255-262. **Imaging Lead**. [Original Article].

24. Downes M, Perlis N, Loblaw A, **Ghai S**, van der Kwast T. Target prostate biopsies: how best to report in synoptic format? *Can Urol Assoc J (CUAJ)*. *Can Urol Assoc J*. 2022 Apr;16(4):E227-E230. **Imaging Lead**. [guidelines]
25. Basso Dias A, O'Brien C, Correias MJ, **Ghai S**. Multiparametric Ultrasound and Micro-ultrasound in Prostate Cancer: A Comprehensive Review. *Br J Radiol*. 2022 Mar 1;95(1131):20210633. **Senior Responsible Author**. [Review Article]
26. **Ghai S**, O'Brien C, Goldstein DP, Sawka AM. Ultrasound in active surveillance for low-risk papillary thyroid cancer: imaging considerations in case selection and disease surveillance. *Insights in Imaging* 2021 Sept 16; 12(1):130. **Principal Author**. [Original Article]
27. Dos Santos DN, Horvat N, Basso Dias A, Mota M, Veloso G, Schoen K, **Ghai S**, Queiroz M, Viana P. Prostate Cancer: What we already know and what is on the horizon. *Radiographics* 2022 May 27. **Coauthor**. [Pictorial Review]
28. Paxton M, Barbalat E, Perlis N, Menezes RJ, Gertner M, Dragas D, Haider MA, Finelli A, Trachtenberg J, **Ghai S**. Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer. *Br J of Radiology* 2021 Jul 29: 20210414. **Senior Responsible Author**. [Original Article]
29. Chang SD, **Ghai S**, Kim CK, Oto A, Giganti F, Moore CM. MRI-targeted prostate biopsy technique: *AJR* expert panel narrative review. *Am J Roentgenol*. 2021 Oct 13: 1-19. Online ahead of print. **Coauthor**. [Review article]
30. Madariaga A, Bhat G, Wilson MK, Li X, Cyriac S, Bowering V, Hunt W, Gutierrez D, Bonilla L, Kasherman L, McMullen M, Wang L, **Ghai S**, Dhani NC, Oza AM, Lheureux S. Research Biopsies in gynecologic oncology: patient-reported outcomes, perceptions and preferences. *Am J Obstet Gynecol*. 2021 Jun 23: S0002-9378(21)00707-7. **Imaging Lead**. [Original Article]
31. Deniffel D, Healy GM, Dong X, **Ghai S**, Salinas-Miranda E, Fleshner N, Hamilton R, Kulkarni G, Toi A, van der Kwast T, Zlotta A, Finelli A, Perlis N, Haider M. Avoiding unnecessary biopsy: MRI-based risk models versus a PI-RADS and PSA density strategy for clinically significant prostate cancer. *Radiology*. May 2021 doi:10.1148/radiol.2021204112. Online ahead of print. **Coauthor**. [Original Article]
32. Magee D, Perlis N, Corr K, Chan R, Gertner M, Zisman A, Jokhu S, **Ghai S**. Salvage interstitial laser thermal therapy under MRI guidance (MRgFLA) for high-intensity focal ultrasound (HIFU) recurrences: feasibility study. *Clinical Imaging*. 27 Apr 21. 76:217-221 <https://doi.org/10.1016/j.clinimag.2021.04.014>. **Senior Responsible Author**. [Original Article]
33. Metser U, Ortega C, Perlis N, Lechtman E, Berlin A, Anconina R, Eshet Y, Chan R, Veit-Haibach P, van der Kwast T, Liu A, **Ghai S**. Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR. *Eur J Nucl Med Mol Imaging*. 2021 Oct;48(11):3702-3711. **Senior Responsible Author**. [Original Article]
34. Finelli A, Komisarenko M, Martin L J, Timilshina V, Jain K, Morris J, Zlotta A, Kulkarni G, Perlis N, van der Kwast T, Evans A, **Ghai S**, Fleshner N, Alibhai S M H, Hamilton R J. Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer. *Prostate Cancer Prostatic Dis*. 2021 Mar;24(1):69-76. doi: 10.1038/s41391-020-0218-2.Epub. **Coauthor**. [Original Article]
35. Sawka A, **Ghai S**, Tomlinson G, Baxter N, Corsten M, Imran SA, Bissada E, Leboeuf R, Audet N, Brassard M, Zhang H, Gupta M, Nichols AC, Morrison D, Johnson-Obeski S, Prisman E, Anderson D, Chandarana SP, Ghaznavi S, Jones J, Gafni A, Matelski JJ, Xu W, Goldstein DP. A Protocol for a Pan-Canadian Prospective Observational Study on Active Surveillance or Surgery for Very Low Risk Papillary Thyroid Cancer. *Journal: Frontiers in Endocrinology*. 2018 Apr 12;8(4): e020298. doi: 10.1136/bmjopen-2017-020298. **Imaging Lead**. [Protocol development]
36. Goldstein DP, **Ghai S**, Corsten M, Audet N, Zhang H, Bissada E, Nichols A, Morrison D, Johnson-Obeski S, Anderson D.W, Prisman E, Baxter N.N, Jones J, Gafni A, Witterick I, Sawka A.M. Proceedings of the Canadian

- Thyroid Cancer Active Surveillance Study Group 2019 National Investigator Meeting. *Journal of Otolaryngol Head Neck Surg.* 2021 Jun 25;50(1):40. doi: 10.1186/s40463-021-00514-0. **Imagign Lead.** [Review]
37. Pavlovich CP, Hyndman ME, Eure G, **Ghai S**, Caumartin Y, Rosenfeld B, Herget E, Young JD, Wiseman D, Coughlin C, Gray R, Wason S, Lodde M, Toi A, Dujardin T, Lance R, Schatz SM, Fabrizio M, Malcom JB, Fradet VA. Multi-institutional randomized controlled trial comparing first generation transrectal high-resolution micro-ultrasound with conventional frequency transrectal ultrasound for prostate biopsy. *BJUI Compass* 2021 Mar;2(2):126–33. **Local PI in multi-center trial.** [Original Article]
 38. Avery A, Sussman M, Longo J, Menezes RJ, Hamilton RJ, van der Kwast TH, Fleshner NE, Penn LZ, **Ghai S**. Quantitative Prostate MRI analysis following Fluvastatin therapy for localised prostate cancer - a pilot study. *Can Assoc Radiol J.* 2021 Feb 10;846537120988262. doi: 10.1177/0846537120988262. Impact Factor 1.72 (Trainee publication, Avery A, Fellow). **Senior Responsible Author** [Original Article].
 39. Klotz L, Chin J, Black P, Finelli A, Anidjar M, Bladou F, Machado A, Levental M, **Ghai S**, Chang S, Milot L, Patel C, Kassam Z, Moore C, Kasivisanathan V, Loblaw A, Kebabdjian M, Earle C, Pond G, Haider M. Multi-parametric MRI-targeted biopsy compared to systematic TRUS biopsy for biopsy naïve men at risk for prostate cancer, A phase 3 randomized clinical trial. *JAMA Oncol.* 2021 Apr 1;7(4):534-542. doi: 10.1001/jamaoncol.2020.7589. Online ahead of print. Impact Factor 24.8. **Institutional PI.** [Original Article]
 40. **Ghai S**, Finelli A, Corr K, Chan R, Jokhu S, Li X, McCluskey S, Konukhova A, Hlasny E, van der Kwast TH, Incze PF, Zlotta AR, Hamilton RJ, Haider MA, Kucharczyk W, Perlis N. MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer: early results of a phase II trial. *Radiology.* 2021 Mar;298(3):695-703 doi: 10.1148/radiol.2021202717. Impact Factor 11.1. **Principal Author.** [Original Article].
 41. Sawka A, **Ghai S**, Ihekire O, Jones JM, Gafni A, Baxter NN, Goldstein DP. Decision-making in Surgery or Active Surveillance for Low Risk Papillary Thyroid Cancer During the COVID-19 Pandemic. *Cancers (Basel).* 2021 Jan 20;13(3):371. doi: 10.3390/cancers13030371. Impact Factor 6.1. **Imagign Lead.** [Original Article]
 42. Qaoud Y, Bettoli P, Sanmamed-Salgado N, Herrera-Caceres JO, Berjaoui MB, Lajkosz Almeida K, Goldberg H, Woon DTS, Glase Z, **Ghai S**, Finelli A, Chung P, Perlis N, Fleshner, NE, Berlin A. Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer- Functional and Oncological Outcomes. *Eur Urol Open Sci.* 2020. 21:1-4. **Coauthor.** [Original Article].
 43. Atri A, Menezes RJ, Boerner SL, Incze T, Ciapanna C, Jia Y, Boci R, Maan KA, Javed W, **Ghai S**. Long-Term Impact of Thyroid Biopsy Specialists on Efficiency and Quality of Thyroid Biopsy. *J Am Coll Radiology* 2021 Feb;18(2):274-279. doi: 10.1016/j.jacr.2020.07.011. Epub 2020 Aug 6. Impact Factor 4.3 (Trainee publication, Atri A, Graduate student). **Senior Responsible Author.**[Original Article].
 44. Deniffel D, Salinas E, Ientilucci M, Evans AJ, Fleshner, NE, **Ghai S**, Hamilton R, Roberts A, Toi A, van der Kwast T, Zlotta A, Finelli A, Haider MA, Perlis N. **Reply by authors:** Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes? *J Urol.* 2020; doi: 10.1097/JU.0000000000001157. Online ahead of print. Impact Factor 5.9. **Coauthor.** [Original Article].
 45. Perlis N, Finelli A, Lovas M, Berlin A, Papadacos J, **Ghai S**, Bakas V, Alibhai S, Lee O, Badzynski A, Wiljer D, Lund A, Di Meo A, Cafazzo J, Haider M. Creating patient-centered radiology reports to empower patients undergoing prostate magnetic resonance imaging. *Can Urol Assoc J.* 2020 Sep 28. doi: 10.5489/cuaj.6585. Online ahead of print. Impact Factor 1.4. **Coauthor.** [Original Article].
 46. Deniffel D, Salinas E, Ientilucci M, Evans AJ, Fleshner, NE, **Ghai S**, Hamilton R, Roberts A, Toi A, van der Kwast T, Zlotta A, Finelli A, Haider MA, Perlis N. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes? *J Urol.* 2020 Dec;204(6):1187-1194. doi: 10.1097/JU.0000000000001157. Epub 2020 Jun 4. Impact Factor 5.9. **Coauthor.** [Original Article]
 47. Sanmamed N, Lee J, Berlin A, Craig T, Lao B, Rink A, Bayley A, Catton C, Sundaramurthy A, Foltz W, McPartlin A, **Ghai S**, Astenafu E, Gospodarowicz M, Warde P, Ménard C, Chung P. Tumor-targeted dose

- escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. *Radiother Oncol.* 2020 Aug;149:240-245. doi: 10.1016/j.radonc.2020.05.029. Epub 2020 May 22. Impact Factor 4.9. **Coauthor.**
48. Lebastchi AH, George AK, Polascik TJ, Coleman J, de la Rosette J, Turkbey B, Wood BJ, Gorin MA, Sidana A, **Ghai S**, Tay KJ, Ward JF, Sanchez-Salas R, Muller BG, Malavaud B, Mozer P, Crouzet S, Choyke PL, Ukimura O, Rastinehad AR, Pinto PA. Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international multidisciplinary consensus. *Eur Urol.* 2020 Sep;78(3):371-378. doi: 10.1016/j.eururo.2020.05.018. Epub 2020 Jun 10. Impact Factor 17.6. **Coauthor.**
49. Westphalen AC, McCulloch CE, Anaokar JM, Arora S, Barashi NS, Barentsz JO, Bathala TK, Bittencourt LK, Booker MT, Braxton VG, Carroll PR, Casalino DD, Chang SD, Coakley FV, Dhatt R, Eberhardt SC, Foster BR, Froemming AT, Fütterer JJ, Ganeshan DM, Gertner MR, Mankowski Gettle L, **Ghai S**, Gupta RT, Hahn ME, Houshyar R, Kim C, Kim CK, Lall C, Margolis DJA, McRae SE, Oto A, Parsons RB, Patel NU, Pinto PA, Polascik TJ, Spilseth B, Starcevich JB, Tammisetti VS, Taneja SS, Turkbey B, Verma S, Ward JF, Warlick CA, Weinberger AR, Yu J, Zagoria RJ, Rosenkrantz AB. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI Across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. *Radiology.* 2020 Jul;296(1):76-84. doi: 10.1148/radiol.2020190646. Epub 2020 Apr 21. Impact Factor 7.9. **Coauthor.**
50. Correas JM, Halpern EJ, Barr RG, **Ghai S**, Walz J, Bodard S, Dariane C, de la Rosette J. Advanced ultrasound in the diagnosis of prostate cancer. *World J Urol.* 2020 Apr 18. doi: 10.1007/s00345-020-03193-0. Online ahead of print. Impact Factor 3.0. **Coauthor.**
51. Koshkina A, Fazelzad R, Sugitani I, Miyauchi A, Thabane L, Goldstein DP, **Ghai S**, Sawka AM. Association of patient age with progression of low-risk papillary thyroid carcinoma under active surveillance: a systematic review and meta-analysis. *JAMA Otolaryngol Head Neck Surg.* 2020 Jun 1;146(6):552-560. doi: 10.1001/jamaoto.2020.0368. Impact Factor 3.85. **Coauthor.**
52. Sawka AM, **Ghai S**, Yoannidis T, Rotstein L, Gullane PJ, Gilbert RW, Pasternak JD, Brown DH, Eskander A, de Almeida JR, Irish JC, Higgins K, Enepekides DJ, Monteiro E, Banerjee A, Shah M, Gooden E, Zahedi A, Korman M, Ezzat S, Jones JM, Rac VE, Tomlinson G, Stanimirovic A, Gafni A, Baxter NN, Goldstein DP. A Prospective mixed-methods study of decision-making on surgery or active surveillance for low-risk papillary thyroid cancer. *Thyroid.* 2020 Jul;30(7):999–1007. doi: 10.1089/thy.2019.0592. Epub 2020 Apr 8. Impact Factor 5.22. **Coauthor.**
53. **Ghai S.** Editorial Comment: Prostate Mapping for cancer diagnosis: The Madrid protocol. Transperineal prostate biopsies using multiparametric magnetic resonance imaging fusion and micro-ultrasound guided biopsies. *J Urol* 2020 Oct;204(4):732-733. doi: 10.1097/JU.0000000000001083.02. Epub 2020 Jul 30. Impact Factor 5.9. **Principal Author.**
54. **Ghai S.** Editorial Comment: Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer. *J Urol.* 2020 May;203(5):923-924. doi: 10.1097/JU.0000000000000692.01. Epub 2020 Feb 20. Impact Factor 5.9. **Principal Author.**
55. Perlis N, **Ghai S**, Tan GH, Finelli A. What are the limits of focal therapy for localized prostate cancer? For: GG3-5 may be considered. *Eur Urol Focus.* 2020 Mar 15;6(2):201-202. doi: 10.1016/j.euf.2019.04.019. Epub 2019 May 3. Impact Factor 4.82. **Coauthor.**
56. Longo J, Hamilton RJ, Masoomian M, Khurram N, Branchard E, Mullen PJ, Elbaz M, Hersey K, Chadwick D, **Ghai S**, Andrews DW, Chen EX, van der Kwast TH, Fleshner, NE, Penn LZ. A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. *Prostate Cancer Prostatic Dis.* 2020 Dec;23(4):630-637. doi: 10.1038/s41391-020-0221-7. Epub 2020 Mar 13. Impact Factor 4.3. **Coauthor.**
57. Klotz L, Pond G, Loblaw A, Sugar L, Moussa M, Berman D, Van der Kwast T, Vesprini D, Milot L, Kebabdjian M, Fleshner N, **Ghai S**, Chin J, Haider M. Randomized Study of Systematic Biopsy Versus Magnetic

Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. *Eur Urol.* 2020 Mar;77(3):311-317. doi: 10.1016/j.eururo.2019.10.007. Impact Factor 17.6. **Coauthor.**

58. He J, Li CL, Wilson BC, Fisher CJ, **Ghai S**, Weersink RA. A Clinical Prototype Transrectal Diffuse Optical Tomography (TRDOT) System for In vivo Monitoring of Photothermal Therapy (PTT) of Focal Prostate Cancer. *IEEE Trans Biomed Eng.* 2019 Nov 25;67(7):2119–2129. doi: 10.1109/TBME.2019.2955354. [Epub ahead of print]. Impact Factor 4.78. **Coauthor.**
59. **Ghai S.** Editorial Comment: Study of Prostate Ablation Related Energy Devices (SPARED) Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. *J Urol.* 2019 Nov;202(5):958 doi: 10.1097/01.JU.0000579312.61159.39. Epub 2019 Oct 9. Impact Factor 5.9. **Principal Author.**
60. Kundra A, Goldstein DP, Wintemute K, **Ghai S**, Tsang RW, Gupta K, Mutasingwa DR, Weissberger J, Huszti E, Brown P, Jiang H, Sawka, AM. A Pilot Study Examining Toronto-area Family Physician Perspectives on Thyroid Neoplasm Evaluation. *J Otolaryngol Head Neck Surg.* 2019 May 30;48(1):24. doi: 10.1186/s40463-019-0349-4. Impact Factor 2.31. **Coauthor.**
61. Lo G, Burton KR, Haider MA, Fleshner NE, Finelli A, **Ghai S.** Reply: Negative predictive value of prostate multi-parametric magnetic resonance imaging among men with negative prostate biopsy and elevated PSA: a clinical outcome retrospective cohort study. *J Urol.* 2019 Dec;202(6):1159-1165. Impact Factor 5.9. **Senior Responsible Author.**
62. Sanmamed N, Chung P, Berlin A, Adleman J, Borg J, Lao B, **Ghai S**, Weersink R, Simeonov A, Rink A, Ménard C, Helou J. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life. *Brachytherapy.* 2019 Jul-Aug;18(4):477-483. doi: 10.1016/j.brachy.2019.02.003. Epub 2019 May 17. Impact Factor 1.85. **Coauthor.**
63. Lo G, Burton K.R, Haider M.A, Fleshner, N. E, Finelli A, **Ghai S.** Negative predictive value of prostate multi-parametric magnetic resonance imaging among men with negative prostate biopsy and elevated PSA: a clinical outcome retrospective cohort study. *J Urol.* 2019 Dec;202(6):1159-1165. doi: 10.1097/JU.0000000000000388. Epub 2019 Jun 12. Impact Factor 5.9 (Trainee publication, Lo G, Fellow). **Senior Responsible Author.**
64. Marotta B, Chaudhry S, McNaught A, Queresby F, Vajpeyi R, Chetty R, **Ghai S.** Predicting Underlying Neoplasms in Appendiceal Mucocoeles at CT: Focal Versus Diffuse Luminal Dilatation. *AJR Am J Roentgenol.* 2019 Aug; 213(2):343-348. doi: 10.2214/AJR.18.20562. Epub 2019 Apr 11. Impact Factor 3.0 (Trainee publication, Marotta B, Resident). **Senior Responsible Author.**
65. **Ghai S**, Trachtenberg J. Internet information on focal prostate cancer therapy: help or hindrance? *J. Nat Rev Urol.* 2019 Jun;16(6):337-338. doi: 10.1038/s41585-019-0180-8. Impact Factor 9.3. **Principal Author.**
66. Pang Z, Margolis M, Menezes RJ, Maan H, **Ghai S.** Diagnostic performance of 2015 American Thyroid Association guidelines and inter-observer variability in assigning risk category. *Eur J Radiol Open.* 2019 Mar 27;6:122-127. doi: 10.1016/j.ejro.2019.03.002. Impact Factor 0.6 (Trainee publication, Pang Z, Fellow). **Senior Responsible Author.**
67. Clouthier DL, Lien SC, Yang S, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, **Ghai S**, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL. An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE). *J Immunother Cancer.* 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0. Impact Factor 10.25. **Coauthor.**
68. Goldberg H, Ramiz AH, Glicksman R, Salgado NS, Chandrasekar T, Klaassen Z, Wallis CJD, Hosni A, Moraes FY, **Ghai S**, Kulkarni GS, Hamilton RJ, Perlis N, Toi A, Chung P, Evans A, van der Kwast T, Finelli A, Fleshner NE, Berlin A. Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable

Prostate Cancer. *Eur Urol Oncol*. 2019 Feb;2(1):88-96. doi: 10.1016/j.euo.2018.05.003. Impact Factor 0.74. **Coauthor.**

69. Tau N, Berlin A, Yeung I, Halankar J, Murphy G, Jhaveri KS, **Ghai S**, Metser U. Quantitative assessment of dynamic 18F-flumethycholine PET and dynamic contrast enhanced MRI in high risk prostate cancer. *Br J Radiol*. 2019 Feb;92(1094):20180568. doi: 10.1259/bjr.20180568. Impact Factor 2.2. **Coauthor.**
70. van Luijtelaa A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, McClure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, **Ghai S**, Fütterer JJ. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. *World J Urol*. 2019 Oct; 37(10):2147-2153. doi: 10.1007/s00345-019-02636-7. Epub 2019 Jan 22. Impact Factor 3.0 (Trainee publication, van Luijtelaa A, Master's student). **Co-Senior Responsible Author.**
71. Metser U, Chan R, Veit-Haibach P, **Ghai S**, Tau N. Comparison of MRI sequences in whole-body pet/mri for staging of patients with high-risk prostate cancer. *AJR Am J Roentgenol*. 2019 Feb;212(2):377-381 doi: 10.2214/AJR.18.20495. Epub 2018 Oct 17. Impact Factor 3.0. **Coauthor.**
72. Aung KL, Bedard PL, Yu C, Boerner SL, Zuzarte PC, **Ghai S**, Berman HK, Serra S, Giesler A, Ahmed L, Joshua AM, Moore MJ, Oza AM, Amir E, McPherson JD, Zhang T, Sukhai MA, Stockley TL, Kamel-Reid S, Siu LL, Hansen AR. Minimally invasive real-time detection of actionable mutations in patients with metastatic solid tumors using fine-needle and liquid biopsies. *JCO Precis Oncol*. 2018;2:1-20. doi: 10.1200/PO.17.00248. Epub 2018 Jun 29. **Coauthor.**
73. Cornud F, Bomers J, Fütterer JJ, **Ghai S**, Reijnen JS, Tempany C. MR-imaging guided prostate intervention: ready for clinical use? *Diagn Interv Imaging*. 2018 Nov; 99(11):743-753. doi: 10.1016/j.diii.2018.08.002. Epub 2018 Sep 3. Impact Factor 2.5. **Coauthor.**
74. Eure G, Fanney D, Lin J, Wodlinger B, **Ghai S**. Comparison of conventional transrectal ultrasound, magnetic resonance imaging, and micro-ultrasound for visualizing prostate cancer in an active surveillance population: A feasibility study. *Can Urol Assoc J*. 2019 Mar;13(3):E70-E77. doi: 10.5489/cuaj.5361. Epub 2018 Aug 30. Impact Factor 1.4. **Senior Responsible Author.**
75. Mathur S, O'Malley ME, **Ghai S**, Jhaveri K, Sreeharsha B, Margolis M, Zhong L, Maan H, Toi A. Correlation of 3T multiparametric prostate MRI using prostate imaging reporting and data system (PIRADS) version 2 with biopsy as reference standard. *Abdom Radiol (NY)*. 2019 Jan; 44(1):252-258. doi: 10.1007/s00261-018-1696-8. Impact Factor 2.4. **Coauthor.**
76. Klotz L, Loblaw A, Sugar L, Moussa M, Berman DM, Van der Kwast T, Vesprini D, Milot L, Kebabdjian M, Fleshner, N. E, **Ghai S**, Chin J, Pond GR, Haider M. Active surveillance magnetic resonance imaging study (ASIST): results of a randomized multicenter prospective trial. *Eur Urol*. 2019 Feb;75(2):300-309. doi: 10.1016/j.eururo.2018.06.025. Epub 2018 Jul 13. Impact Factor 17.6. **Coauthor.**
77. Tay KJ, Amin MB, **Ghai S**, Jimenez RE, Kench JG, Klotz L, Montironi R, Muto S, Rastinehad AR, Turkbey B, Villers A, Polascik TJ. Surveillance after prostate focal therapy. *World J Urol*. 2019 Mar;37(3):397-407. doi: 10.1007/s00345-018-2363-y. Epub 2018 Jun 9. Impact Factor 3.0. **Coauthor.**
78. Lodeizen O, de Bruin M, Eggener S, Crouzet S, **Ghai S**, Varkarakis I, Katz A, Dominguez-Escrig JL, Pahernik S, de Reijke T, de la Rosette. Ablation energies for focal treatment of prostate cancer. *World J Urol*. 2019 Mar; 37(3):409-418. doi: 10.1007/s00345-018-2364-x. Epub 2018 Jun 25. Impact Factor 3.0. **Coauthor.**
79. Sawka AM, **Ghai S**, Tomlinson G, Rotstein L, Gilbert R, Gullane P, Pasternak J, Brown D, de Almeida J, Irish J, Chepeha D, Higgins K, Monteiro E, Jones JM, Gafni A, Goldstein DP. A protocol for a Canadian prospective observational study of decision-making on active surveillance or surgery for low-risk papillary thyroid cancer. *BMJ Open*. 2018 Apr 12;8(4):e020298. doi: 10.1136/bmjopen-2017-020298. Impact Factor 2.5. **Coauthor.**

80. Prendeville S, Gertner M, Maganti M, Pintilie M, Perlis N, Toi A, Evans AJ, Finelli A, van der Kwast TH, **Ghai S**. Role of magnetic resonance imaging targeted biopsy in detection of prostate cancer harboring adverse pathological features of intraductal carcinoma and invasive cribriform carcinoma. *J Urol*. 2018 Jul;200(1):104-113. doi: 10.1016/j.juro.2018.01.081. Epub 2018 Feb 2. Impact Factor 5.9 (Trainee publication, Prendeville S, Pathology Fellow). **Senior Responsible Author**.
81. Chandrasekar T, Goldberg H, Klaassen Z, Perlis N, Finelli A, Evans A, **Ghai S**. Case - Foamy, high-grade prostatic intraepithelial neoplasia: A false positive for prostate cancer on multiparametric magnetic resonance imaging? *Can Urol Assoc J*. 2018 May;12(5):E256-E259. doi: 10.5489/cuaj.4860. Epub 2018 Feb 6. Impact Factor 1.4 (Trainee publication, Chandrasekar T, Urology Fellow). **Senior Responsible Author**.
82. Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, O'Kane GM, Albaba H, Moura S, Grant RC, Miller JK, Mbabaali F, Pasternack D, Lungu IM, Bartlett JMS, **Ghai S**, Lemire M, Holter S, Connor AA, Moffitt RA, Yeh JJ, Timms L, Krzyzanowski PM, Dhani N, Hedley D, Notta F, Wilson JM, Moore MJ, Gallinger S, Knox JJ. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS Trial. *Clin Cancer Res*. 2018 Mar 15;24(6):1344-1354. doi: 10.1158/1078-0432.CCR-17-2994. Epub 2017 Dec 29. Impact Factor 10.1. **Coauthor**.
83. **Ghai S**, Van der Kwast T. Suspicious findings on micro-ultrasound imaging and early detection of prostate cancer. *Urol Case Rep*. 2017 Nov 21;16:98-100. doi: 10.1016/j.eucr.2017.11.013. ecollection 2018 Jan. **Principal Author**.
84. Perlis N, Al-Kasab T, Ahmad A, Goldberg E, Fadak K, Sayid R, Finelli A, Kulkarni G, Hamilton R, Zlotta A, **Ghai S**, Fleshner N. Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. *J Urol*. 2018 May;199(5):1182-1187. doi: 10.1016/j.juro.2017.11.074. Epub 2017 Nov 23. Impact Factor 5.9. **Coauthor**.
85. Spilseth B, Margolis DJ, **Ghai S**, Patel NU, Rosenkrantz AB. Radiologists' preferences regarding content of prostate MRI reports: a survey of the Society of Abdominal Radiology. *Abdom Radiol (NY)*. 2018 Jul;43(7):1807-1812. doi: 10.1007/s00261-017-1393-z. Impact Factor 2.4. **Coauthor**.
86. Spilseth B, **Ghai S**, Patel NU, Taneja SS, Margolis DJ, Rosenkrantz AB. A Comparison of Radiologists' and Urologists' Opinions Regarding Prostate MRI Reporting: Results from a Survey of Specialty Societies. *AJR Am J Roentgenol*. 2018 Jan;210(1):101-107. doi: 10.2214/AJR.17.18241. Epub 2017 Oct 24. Impact Factor 3.0. **Coauthor**.
87. **Ghai S**, Perlis N, Lindner U, Hlasny E, Haider MA, Finelli A, Zlotta AR, Kulkarni GS, van der Kwast TH, McCluskey SA, Kucharczyk W, Trachtenberg J. Magnetic Resonance Guided Focused High Frequency Ultrasound Ablation for Focal Therapy in Prostate Cancer - Phase 1 Trial. *Eur Radiol* 2018 Oct;28(10):4281-4287. doi: 10.1007/s00330-018-5409-z. Epub 2018 Apr 25. Impact Factor 4.1. **Principal author**.
88. Metser U, Berlin A, Halankar J, Murphy G, Jhaveri KS, **Ghai S**, Tau N. 18F-Fluorocholine PET-whole body MR in the staging of high risk prostate cancer. *AJR Am J Roentgenol*. 2018 Mar;210(3):635-640. doi: 10.2214/AJR.17.18567. Epub 2018 Jan 11. Impact Factor 3.0. **Coauthor**.
89. **Ghai S**. Editorial Comment: Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance. *J Urol* 2017 Oct;198(4):839-847. doi: 10.1016/j.juro.2017.04.119. Epub 2017 Jun 29. Impact Factor 5.9. **Principal author**.
90. Tay KJ, Scheltema M, Ahmed H, Barret E, Coleman J, Dominguez-Escrig J, **Ghai S**, Huang J, Jones S, Klotz L, Robertson C, Sanchez-Salas R, Scionti S, Sivaraman A, De la Rosette JJ, Polascik TJ. Patient selection for Prostate Focal Therapy in the Era of Active Surveillance: An International Delphi Consensus Project. *Prostate Cancer Prostatic Dis*. 2017 Sep;20(3):294-299. Impact Factor 4.3. **Coauthor**.
91. Perlis N, Sayyid R, Evans A, Van Der Kwast T, Toi A, Finelli A, Kulkarni G, Hamilton R, Zlotta AR, Trachtenberg J, **Ghai S**, Fleshner NE. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. *J Urol* 2017 Jan;197(1):75-83. doi: 10.1016/j.juro.2016.07.076. Epub 2016 Jul 22. Impact Factor 5.9. **Coauthor**.

92. Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Barret E, Baumunk D, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Dominguez-Escrig J, Eggener S, Ganzer R, **Ghai S**, Gill IS, Gupta R, Henkel TO, Hohenfellner M, Jones S, Kahmann F, Kastner C, Köhrmann KU, Kovacs G, Miano R, van Moorselaar RJ, Mottet N, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sanchez-Salas R, Schostak M, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJ. Standardization in Definitions in Focal Therapy in Prostate Cancer: report from a Delphi consensus project. *World J Urol.* 2016 Oct;34(10):1373-82. Impact Factor 3.0. **Coauthor.**
93. **Ghai, S**, Eure, G, Fradet, V, Hyndman, ME, McGrath, T, Wodlinger, B, Pavlovich, CP. Assessing Cancer Risk on Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification. *J Urol.* 2016 Aug;196(2):562-9. doi: 10.1016/j.juro.2015.12.093. Epub 2016 Jan 12. Impact Factor 5.9. **Principal Author.**
94. Muller BG, van den Bos W, Brausi M, Fütterer JJ, **Ghai S**, Pinto PA, Popeneciu IV, de Reijke TM, Robertson C, de la Rosette JJ, Scionti S, Turkbey B, Wijkstra H, Ukimura O, Polascik TJ. Follow-up Modalities in Focal Therapy for Prostate Cancer: Results from a Delphi Consensus Project. *World J Urol.* 2015 Oct;33(10):1503-9. Impact Factor 3.0. **Coauthor.**
95. **Ghai S**, Lee SY, Bret PM, Menezes RJ, Boerner SL, Jia Y, Maan KA, Boci R, Javed W, Atri M. Thyroid biopsy specialists: a quality initiative to reduce wait times and improve adequacy rates. *Radiology* 2015 Sep;276(3):894-9. doi: 10.1148/radiol.2015140620. Epub 2015 Apr 20. Impact Factor 7.9 (Trainee publication, Lee SY, Fellow). **Principal Author.**
96. **Ghai S**, Louis AS, Van Vliet M, Lindner U, Haider MA, Hlasny E, Spensieri P, van der Kwast TH, McCluskey S, Kucharczyk W, Trachtenberg J. Real-time MRI-guided focused ultrasound for focal therapy of locally confined low-risk prostate cancer: feasibility and preliminary outcomes. *AJR Am J Roentgenol.* 2015 Aug;205(2):W177-84. doi: 10.2214/AJR.14.13098. Impact Factor 3.0 (Trainee publication, Louis AS, Medical student). **Principal Author.**
97. **Ghai S**, Haider MA. Multiparametric MRI in diagnosis of prostate cancer (Invited Review). *Indian Journal of Urology (Recent advances in urologic imaging symposium).* *Indian J Urol.* 2015 Jul-Sep;31(3):194-201. doi: 10.4103/0970-1591.159606. Impact Factor 0.9. **Principal Author.**
98. **Ghai S**, Trachtenberg J. MRI guided biopsies and minimally invasive therapy for prostate cancer (invited review). *Indian Journal of Urology (Recent advances in urologic imaging symposium).* *Indian J Urol.* 2015 Jul-Sep;31(3):209-16. doi: 10.4103/0970-1591.159615. Impact Factor 0.9. **Principal Author.**
99. Al-Edwan GM, **Ghai S**, Margel D, Kulkarni GS, Hamilton RT, Toi A, Haider MA, Finelli A, Fleshner NE. Magnetic resonance imaging detected prostate evasive anterior tumor: further insights. *Can Urol Assoc J.* 2015 May-Jun;9(5-6):E267-72. doi: 10.5489/cuaj.2562. Impact Factor 1.4 (Trainee publication, Al-Edwan GM, Urology Fellow). **Co-Principal Author.**
100. **Ghai S**, Trachtenberg J. In-bore MRI interventions: current status and future directions (invited review). *Current Opinion in Urology (Focal therapy of prostate cancer issue).* *Curr Opin Urol.* 2015 May;25(3):205-11. doi: 10.1097/MOU.000000000000160. Impact Factor 2.15. **Principal Author.**
101. Arraiza M, Metser U, Khalili K, Hanbidge A, Vajpeyi R, Kennedy E, **Ghai S**. Primary cystic peritoneal masses and mimickers: spectrum of diseases with pathologic correlation. *Abdom Imaging.* 2015 Apr;40(4):875-906. doi: 10.1007/s00261-014-0250-6. Impact Factor 1.6. (Trainee publication, Arraiza M, Fellow). **Senior Responsible Author.**
102. Cepek J, Lindner U, **Ghai S**, Louis AS, Davidson SR, Gertner M, Hlasny E, Sussman MS, Fenster A, Trachtenberg J. Mechatronic System for In-Bore MRI-Guided Insertion of Needles to the Prostate: An in vivo Needle Guidance Accuracy Study. *J Magn Reson Imaging.* 2015 Jul;42(1):48-55. doi: 10.1002/jmri.24742. Epub 2014 Sep 4. Impact Factor 3.95. **Coauthor.**
103. **Ghai S**, Trachtenberg J. Prostate cancer: a consensus on trial design for focal therapy. *Nat Rev Urol.* 2014 Apr;11(4):190-2. doi: 10.1038/nrurol.2014.64. Epub 2014 Mar 18. Impact Factor 9.33. **Principal Author.**

104. Brennan C, Kajaal D, Khalili K, **Ghai S**. Solid malignant retroperitoneal masses: a pictorial review. *Insights Imaging*. 2014 Feb;5(1):53-65. doi: 10.1007/s13244-013-0294-0. Epub 2013 Nov 29. Impact Factor 3.58 (Trainee publication, Brennan C, Fellow). **Senior Responsible Author**.
105. Cepek J, Lindner U, Davidson SRH, Haider MA, **Ghai S**, Trachtenberg J, Fenster A. Treatment planning for prostate focal laser ablation in the face of needle placement uncertainty. *Med Phys*. 2014 Jan;41(1):013301. doi: 10.1118/1.4842535. Impact Factor 3.2. **Coauthor**.
106. Murphy G, Haider M, **Ghai S**, Sreeharsha B. The expanding role of MRI in prostate cancer. *AJR Am J Roentgenol*. 2013 Dec;201(6):1229-38. doi: 10.2214/AJR.12.10178. Impact Factor 3.0. **Coauthor**.
107. Tran B, Brown AM, Bedard PL, Winkquist E, Goss GD, Hotte SJ, Welch SA, Hirte HW, Zhang T, Stein LD, Ferretti V, Watt S, Jiao W, Ng K, **Ghai S**, Shaw P, Petrocelli T, Hudson TJ, Neel BG, Onetto N, Siu LL, McPherson JD, Kamel-Reid S, Dancy JE. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. *Int J Cancer*. 2013 Apr 1;132(7):1547-55. doi: 10.1002/ijc.27817. Epub 2012 Oct 11. Impact Factor 5.15. **Coauthor**.
108. Goldstein MA, Atri M, O'Malley M, Jacks L, John R, Herzenberg A, Reich H, **Ghai S**. Nonfocal renal biopsies: adequacy and factors affecting a successful outcome. *J Comput Assist Tomogr*. 2013 Mar-Apr;37(2):176-82. doi: 10.1097/RCT.0b013e31827bf6a0. Impact Factor 1.3 (Trainee publication, Goldstein MA, Fellow). **Senior Responsible Author**.
109. Goldstein M, Carrillo M, **Ghai S**. Continuous ambulatory peritoneal dialysis: a guide to imaging appearances and complications. *Insights Imaging*. 2013 Feb;4(1):85-92. doi:10.1007/s13244-012-0203-y. Epub 2012 Dec 6. Impact Factor 3.58 (Trainee publication, Goldstein MA, Fellow). **Coauthor**.
110. Lindner U, **Ghai S**, Spensieri P, Hlasny E, van der Kwast TH, McCluskey SA, Haider MA, Kucharczyk W, Trachtenberg J. Focal magnetic resonance guided focused ultrasound for prostate cancer: initial North American experience. *Can Urol Assoc J*. 2012 Dec;6(6):E283-6. doi: 10.5489/cuaj.12218. Impact Factor 1.4 (Trainee publication, Lindner U, Urology Fellow). **Co-Principal Author**.
111. **Ghai S**, Toi A. Role of transrectal ultrasonography in prostate cancer. *Radiol Clin North Am*. 2012 Nov;50(6):1061-73. doi: 10.1016/j.rcl.2012.08.007. Impact Factor 2.0. **Principal Author**.
112. Roberts A, Fanous R, Jaffer NM, McLeod R, Chawla TP, Au WF, **Ghai S**. Guide to surgical procedures on hollow viscera: part 1--esophageal, gastric, and restrictive bariatric procedures. *AJR Am J Roentgenol*. 2012 Jul;199(1):66-75. doi:10.2214/AJR.10.7286. Impact Factor 3.0. **Coauthor**.
113. Roberts A, Fanous R, Jaffer NM, McLeod R, Chawla TP, Au WF, **Ghai S**. Guide to surgical procedures on hollow viscera: part 2--colorectal, ostomy, and malabsorptive bariatric procedures. *AJR Am J Roentgenol*. 2012 Jul;199(1):76-84. doi: 10/2214/AJR.11.7561. Impact Factor 3.0. **Coauthor**.
114. Alshumrani G, O'Malley M, **Ghai S**, Metser U, Kachura J, Finelli A, Mattar K, Panzarella T. Small (≤ 4 cm) cortical renal tumors: characterization with multidetector CT. *Abdom Imaging*. 2010 Aug;35(4):488-93. doi: 10.1007/s00261-009-9546-3. Epub 2009 Jun 18. Impact Factor 1.63. **Coauthor**.
115. Maheshwari E, O'Malley ME, **Ghai S**, Staunton M, Massey C. Split-bolus MDCT urography: upper tract opacification and performance for upper tract tumors in patients with hematuria. *AJR Am J Roentgenol*. 2010 Feb;194(2):453-8. doi: 10.2214/AJR.09.3228. Impact Factor 3.0. **Coauthor**.
116. Lawrentschuk N, Toi A, Lockwood GA, Evans A, Finelli A, O'Malley M, Margolis M, **Ghai S**, Fleshner NE. Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy. *J Urol*. 2009 Dec;182(6):2659-63. doi: 10.1016/j.juro.2009.08.036. Impact Factor 5.9. **Coauthor**.
117. Metser U, **Ghai S**, Ong YY, Lockwood G, Radomski SB. Assessment of urinary tract calculi with 64-MDCT: the axial versus coronal plane. *AJR Am J Roentgenol*. 2009 Jun;192(6):1509-13. doi: 10.2214/AJR.08.1545. Impact Factor 3.0. **Coauthor**.

118. Ramachandra S, Lapsia S, Latifaj B, **Ghai S**. A rare cause of anaemia. *Eur Radiol*. 2008 Jun;18(6):1300-2. doi: 10.1007/s00330-007-0775-y. Epub 2008 May 8. Impact Factor 4.1 (Trainee publication, Ramachandra S, Resident). **Senior Responsible Author**.
119. **Ghai S**, Pattison J, Ghai S, O'Malley ME, Khalili K, Stephens M. Primary gastrointestinal lymphoma: spectrum of imaging findings with pathologic correlation. *Radiographics*. 2007 Sep-Oct;27(5):1371-88. doi: 10.1148/rg.275065151. Impact Factor 4.97. **Principal Author**.
120. Lapsia S, **Ghai S**. Omental infarction: a rare cause of acute abdominal pain. *Emerg Med J*. 2007 Nov;24(11):779. doi: 10.1136/emj.2006.042226. Impact Factor 2.04 (Trainee publication, Lapsia S, Resident). **Senior Responsible Author**.
121. Jhaveri KS, Wong F, **Ghai S**, Haider MA. Comparison of CT histogram analysis and chemical shift MRI in the characterization of indeterminate adrenal nodules. *AJR Am J Roentgenol*. 2006 Nov;187(5):1303-8. doi: 10.2214/AJR.05.1022. Impact Factor 3.0. **Coauthor**.
122. **Ghai S**, Rajan DK, Benjamin MS, Asch MR, Ghai S. Uterine artery embolization for leiomyomas: pre- and postprocedural evaluation with US. *Radiographics*. 2005 Sep-Oct;25(5):1159-72; discussion 1173-6. doi: 10.1148/rg.255045019. Impact Factor 4.97. **Principal Author**.
123. **Ghai S**, Dill-Macky M, Wilson S, Haider M. Fluid-fluid levels in cavernous hemangiomas of the liver: baffled? (Case Report). *AJR Am J Roentgenol*. 2005 Mar;184(3 Suppl):S82-5. doi: 10.2214/ajr.184.3_supplement.01840s82. Impact Factor 3.0. **Principal Author**.
124. Haider MA, **Ghai S**, Jhaveri KS, Lockwood G. Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role? *Radiology*. 2004 Jun;231(3):711-6. Available from: <http://radiology.rsna.org/content/231/3/711.full.pdf>. doi: 10.1148/radiol.2313030676. Epub 2004 Apr 29. Impact Factor 7.9. **Coauthor**.
125. **Ghai S**, Sharma S, Gupta R, Ghai S, Sharma SK, Dey AB. Unusual serosal calcifications in CREST syndrome (Case Report). *Clin Radiol Extra*. 2004 Jan;59(9):91-3. **Coauthor**.
126. **Ghai S**, O'Malley ME. Portal vein gas resulting from ingestion of hydrogen peroxide. *AJR Am J Roentgenol*. 2003 Dec;181(6):1719-20. doi: 10.2214/ajr.181.6.1811719. Impact Factor 3.0. **Principal Author**.
127. **Ghai S**, Sharma R, Ghai S, Kulshreshtha B. Multiorgan involvement in thalassaemia major. *Postgrad Med J*. 2003 Jun;79(932):358, 361-2. doi: 10.1136/pmj.79.932.358. Impact Factor 2.2. **Principal Author**.
128. **Ghai S**, Rajan DK, Asch MR, Muradali D, Simons ME, terBrugge K. Efficacy of embolization in traumatic uterine vascular malformations. *J Vasc Interv Radiol*. 2003 Nov;14(11):1401-8. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=14605105.ui>. doi: 10.1097/01.rvi.0000096761.74047.7d. Impact Factor 2.8. **Principal Author**.
129. Sharma U, **Ghai S**, Paul SB, Gulati MS, Bahl VK, Rajani M, Mukhopadhyay S. Helical CT evaluation of aortic aneurysms and dissection: a pictorial essay (Review). *Clin Imaging*. 2003 Jul-Aug;27(4):273-80. doi: 10.1016/s0899-7071(02)00551-x. Impact Factor 1.2. **Coauthor**.
130. **Ghai S**, Gulati MS. Inner visions: gas mask. *Radiographics*. 2003 Jul;23(4):896. Impact Factor 4.97. **Principal Author**.
131. **Ghai S**, Sharma R, Ghai S. Mixed sclerosing bone dysplasia: a case report with literature review (Review). *Clin Imaging*. 2003 May-Jun;27(3):203-5. doi: 10.1016/s0899-7071(02)00516-8. Impact Factor 1.63. **Principal Author**.
132. Vashisht S, Ghai S, Hatimota P, **Ghai S**, Betharia SM. Cystic lesions of the orbit: a CT spectrum. *Indian J Radiol Imaging*. 2003;13(2):139-44. Available from: <http://www.ijri.org/text.asp?2003/13/2/139/28646>. **Coauthor**.
133. Gupta S, Mohapatra BB, **Ghai S**, Seith A, Kashyap R, Sharma R, Choudhry VP. Haemophilic pseudotumour of the paranasal sinuses: management with radiotherapy and factor replacement therapy (Case Report)

Haemophilia. 2001 Nov;7(6):595-9. Available from: <http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2516.2001.00566.x/pdf>. doi: 10.1046/j.1365-2516.2001.00566.x. Impact Factor 2.6. **Coauthor**.

134. Sharma S, Nabi G, Seth A, Thulkar S, **Ghai S**. Pelvic lipomatosis presenting as uraemic encephalopathy. *Int J Clin Pract*. 2001 Mar;55(2):149-50. Impact Factor 2.6. **Senior Responsible Author**.
135. Thulkar S, **Ghai S**, Sharma S, Lal H. Radiological quiz: musculoskeletal system. *Indian J Radiol Imaging*. 2000;10(2):109-10. Available from: <http://www.ijri.org/text.asp?2000/10/2/109/30616>. **Coauthor**.
136. **Ghai S**, Thulkar S, Purushothaman PN, Sharma S. Multiple focal lesions in liver and spleen in acute leukemia (self-assessment questions). *Postgrad Med J*. 2000;76:661, 664-5. Available from: <http://pmj.bmj.com/content/76/900/661.full.pdf+html>. Impact Factor 2.1. **Principal Author**.
137. Saggar K, **Ghai S**, Khanna S. Imaging diagnosis: necrotizing enterocolitis. *Journal of Applied Medicine*. 1999;25(1):68-9. Impact Factor 1.3. **Coauthor**.
138. Khanna S, Singh AP, **Ghai S**, Ghai S. Imaging diagnosis: ileal duplication cyst. *Journal of Applied Medicine*. 1998;24(11):794-6. Impact Factor 1.3. **Coauthor**.

Book Chapters

1. **Ghai S**, Toi A. Prostate Ultrasound. In: Rumack C, Levine D. *Textbook of Diagnostic Ultrasound*, 6th Edition. Elsevier. 2022. **Principal Author**
2. O'Brien C, Basso Dias A, **Ghai S**. Prostate Imaging. In: D Sutton & B Aggarwal, editors. *Textbook of Radiology and Imaging*. 8th Edition. Volume 1. India: Elsevier. 2022. **Senior Responsible Author**.
3. Mastrocostas K, Lam KM, Ezzat S, **Ghai S**. Endocrine Gland Imaging. In: RM Reilly, editor. *Medical Imaging for Health Professionals: Technologies and Clinical Applications*. Hoboken, NJ: Wiley. 2019. chap. 10; p. 223-262. doi: 10.1002/9781119537397.ch10. **Senior Responsible Author**.
4. Perlis N, Trachtenberg J, **Ghai S**. In-bore Transperineal MRI-Guided Laser Ablation. In: TJ Polascik, editor. *Imaging and Focal Therapy of Early Prostate Cancer*. Current Clinical Urology series. 2nd edition. Cham, Switzerland: Springer International. 2017. chap. 24. doi: 10.1007/978-3-319-49911-6_20. **Principal Author**.
5. McMullen CP, Rocke D, Cl  roux J-F, **Ghai S**, Freeman JL. Ultrasound Characteristics of Non-endocrine Cervical Pathology. In: M Milas, S Mandel & JE Langer, editors. *Advanced Thyroid and Parathyroid Ultrasound*. Cham Switzerland: Springer International; 2017. chap. 23; p. 241-253. doi: 10.1007/978-3-319-44100-9_23. **Coauthor**.
6. **Ghai S**, Trachtenberg J. Surveillance after focal therapy. In: R Sanchez-Salas & M Desai, editors. *Image Guided Therapy in Urology*. SIU-ICUD Joint Consultation on Image-Guided Therapies for Prostate and Kidney Cancers. Montr  al, QC: Soci  t   Internationale d'Urologie (SIU); 2016. chap. 5; p. 355-376. **Principal Author**.
7. **Ghai S**, Trachtenberg J. Available ablation energies to treat prostate cancer. In: R Sanchez-Salas & M Desai, editors. *Image Guided Therapy in Urology*. SIU-ICUD Joint Consultation on Image-Guided Therapies for Prostate and Kidney Cancers. Montr  al, QC: Soci  t   Internationale d'Urologie (SIU); 2016. chap. 4; p. 247-353. **Principal Author**.
7. **Ghai S**, Metser U. Mesentery, omentum, peritoneum: cystic masses and neoplasms. In: B Hamm & PR Ros, editors. *Abdominal imaging*. Berlin, Heidelberg: Springer; 2013. chap. 103; p. 1589-99. Available from: <http://www.springerreference.com/docs/html/chapterdbid/308508.html>. doi: 10.1007/978-3-642-13327-5_170. **Co-Principal Author**.

E. Presentations and Special Lectures

Invited Lectures and Presentations

A) INTERNATIONAL

- 2023 Feb 28 **Invited Speaker.** The Treated Prostate: How to apply Prostate MRI for Local Recurrence Reporting (PI-RR). Society of Abdominal Radiology (SAR) 2015 annual scientific meeting and educational course. Austin, Texas, USA.
- 2022 Nov 30 **Invited Speaker.** Comparison of MicroUS and Multiparametric MRI for Prostate Cancer Detection in Biopsy-Naive Men. Oral presentation at the 108th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA.
- 2022 Nov 29 **Invited Speaker.** MRI guided focused ultrasound ablation (MRgFUS) for localized intermediate-risk prostate cancer -results of a phase II trial. Poster presentation at the 108th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA.
- 2022 Nov 27 **Invited Speaker.** MRI Guided Focal Laser Ablation (MRgFLA) For Localized Intermediate-Risk Prostate Cancer: Results of A Phase II Trial. Oral presentation at the 108th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA
- 2022 Oct 14 **Invited Speaker.** MR-guided focused ultrasound ablation for intermediate risk prostate cancer. Oral presentation at the 13th Interventional MRI Symposium 2022, October 12-14, Leipzig, Germany.
- 2022 Oct 14 **Invited Speaker.** MRI-guided focal laser ablation (MRgFLA) for localized intermediate-risk prostate cancer – results of a phase II trial. Oral presentation at the 13th Interventional MRI Symposium 2022, Leipzig, Germany.
- 2022 Sep 24 **Invited Speaker.** Micro ultrasound and MRI guided Focal Laser Ablation. Sixth Annual Global Summit. Precision Diagnosis and Treatment for Prostate Cancer, Boston, MA, USA.
- 2021 Sep 24 **Invited Speaker.** Focal Therapy: Session: Educational Courses. 38th World Congress of Endourology and Uro-Technology (WCET). Hamburg, Germany at the Hamburg Messe & Congress (CCH)
- 2021 Sep 23 **Invited Speaker.** Debate: Micro Ultrasound vs. MR Fusion for Prostate Cancer: Micro Ultrasound. 38th World Congress of Endourology and Uro-Technology (WCET). Hamburg, Germany at the Hamburg Messe & Congress (CCH)
- 2021 Sep 23-25 **Invited Speaker.** High resolution ultrasound in prostate cancer detection. Fifth Annual Global Summit. Precision Diagnosis and Treatment for Prostate Cancer, Boston, MA, USA. (Virtual)
- 2020 April 24 Prostate Imaging and Focal Therapy Masterclass. London, United Kingdom (Cancelled for COVID).
- 2019 Oct 3-5 **Invited Speaker.** High resolution ultrasound in prostate cancer detection. Fourth Annual Global Summit. Precision Diagnosis and Treatment for Prostate Cancer, Boston, MA, USA.
- 2019 Apr 11-12 **Invited Speaker & Workshop Faculty.** 4th International Workshop on Diagnostic and Interventional Prostate MRI, Hôpital Cochin, Paris Descartes University, Paris, France.
- 2019 Mar 26 **Course director.** Focal Therapy in Localized Prostate Cancer. 2019 Society of Interventional Radiology (SIR) Annual Scientific Meeting. Austin, TX, USA.
- 2019 Mar 19 **Workshop Presenter.** Post treatment Prostate MRI. 2019 Society of Abdominal Radiology (SAR) Annual Scientific Meeting and Educational Course, Orlando, FL, USA.

- 2019 Feb 21-22 **Invited Speaker.** MR guided focal therapy for prostate cancer. Multidisciplinary Meeting on Prostate Cancer. Bilbao, Spain.
- 2019 Feb 9-11 **Invited Speaker.** 'High resolution Ultrasound for detection of Prostate Cancer' 11th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, Kyoto, Japan.
- 2019 Feb 9-11 **Invited Speaker.** 'In Bore MRgFUS focal therapy for prostate cancer' 11th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, Kyoto, Japan.
- 2019 Feb 9-11 **Invited Speaker.** 'A multi-institutional randomized controlled trial comparing novel first generation high-resolution micro-ultrasound with conventional frequency ultrasound for transrectal prostate biopsy' 11th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, Kyoto, Japan.
- 2018 Dec 23 **Invited Speaker & Workshop Faculty.** Prostate MRI Workshop. Organized by All India Institute of Medical Sciences (AIIMS) & Max Superspeciality Hospital, Saket, New Delhi, India.
- 2018 Oct 27 **Invited Speaker.** 'Focal Therapy In Prostate Cancer' 4th Beijing Hospital Prostate Cancer International Conference, Beijing, China.
- 2018 Oct 3-5 **Invited Speaker.** High resolution ultrasound in prostate cancer detection. 4th Global Summit on Precision Diagnosis and Treatment for Prostate Cancer, Boston, MA, USA.
- 2018 Aug 3-5 **Invited Speaker.** 'Real- time High Resolution Micro-Ultrasound for Targeted Biopsies - A Multi-Center Comparison to mpMRI' Third Global Summit on Precision Diagnosis and Treatment for Prostate Cancer, Boston, MA, USA.
- 2018 Aug 3-5 **Panelist.** Session II 'Advanced and Recurrent Prostate Cancer'. 3rd Global Summit on Precision Diagnosis and Treatment for Prostate Cancer, Boston, MA, USA.
- 2018 Mar 6 **Workshop Faculty & Presenter.** 'Focal Therapy' in Prostate Cancer' Society of Abdominal Radiology (SAR) 2018 annual scientific meeting and educational course, Scottsdale, AZ, USA.
- 2017 Oct 13 **Invited Speaker.** Advanced Ultrasound. 2nd Global Summit on Precision Diagnosis for Prostate Cancer, AdMeTech Foundation. Boston, MA, USA.
- 2017 Nov 17 **Invited Speaker.** 'Focal Ablation for Prostate Cancer – State of Art'. Annual meeting of the Asian Conference on Tumor Ablation (ACTA). Gangzhou, China.
- 2017 Mar 28 **Workshop Presenter.** 'Thyroid Nodules: An Approach to Triage Using the 2015 ATA Guidelines' Society of Abdominal Radiology (SAR) 2017 annual scientific meeting and educational course at the Diplomat Resort & Spa in Hollywood, FL, USA. Presenter: **Ghai S.**
- 2017 Jan 29 **Invited Speaker.** 'In-bore biopsy and local therapy for prostate cancer' International Symposium on Urologic Imaging and Intervention', at the All India Institute of Medical Sciences (AIIMS), New Delhi, India.
- 2016 Nov 23 **Presenter.** Micro-ultrasound and new possibilities in prostate cancer. ESUI (EAU Section of Urologic Imaging) 2016, Milan, Italy.
- 2016 June 25 **Panelist.** 'Round table: "It didn't work. Treatment of recurrence with Salvage therapy: which option?" at 9th International Symposium on Focal Therapy and Imaging in prostate and kidney cancer, Durham, NC, USA.
- 2016 June 24 **Invited Speaker.** 'Hot Button debate: Population based MRI screening for PCa – Possible vs practical? – Canadian Perspective' at 9th International Symposium on Focal Therapy and Imaging in prostate and kidney cancer, Durham, NC, USA.
- 2016 June 24 **Invited Speaker.** 'High resolution 29MHz micro-ultrasound' presentation in ESUI Session: Multiparametric prostate ultrasound: Hype or Hope? at 9th International Symposium on Focal Therapy and Imaging in prostate and kidney cancer, Durham, NC, USA.

- 2016 June 24 **Moderator.** 'Round table on High volume Gleason 6: what to do?' at 9th International Symposium on Focal Therapy and Imaging in prostate and kidney cancer, Durham, NC, USA.
- 2016 June 23 **Online Expert Consultant.** Update on patient selection for prostate FT. Consensus project involving 3 rounds of questions according to the Delphi method, 3 days apart (May 19-June 5). Presenter: **Ghai S.**
- 2016 Mar 17 **Workshop Presenter.** 'In-bore Focal Prostate Ablation' Society of Abdominal Radiology (SAR) 2016 annual scientific meeting and educational course in Waikoloa, HI, USA. Presenter: **Ghai S.**
- 2016 Feb 25 **Invited Speaker.** 'Clinical experiences and new possibilities for real-time targeted biopsies using micro-ultrasound' at 3rd Annual Meeting of Individualized Management of Prostate Cancer, Bilbao, Spain. Presenter: **Ghai S.**
- 2015 Sep 18 **Presenter.** Energy Modalities in Focal Therapy of Prostate Cancer. Annual meeting of European Society of Urogenital Radiology (ESUR), Copenhagen, Denmark. Presenter: **Ghai S.**
- 2015 June 22 **Presenter.** 'Laser ablation' Video presentation at 8th International Symposium on Focal Therapy and Imaging in prostate and kidney cancer, Amsterdam, Netherlands. Presenter: **Ghai S.**
- 2015 June 21 **Online Expert Consultant.** Standardization in definitions in focal therapy in prostate cancer. Consensus project involving 3 rounds of questions according to the Delphi method, 3 days apart (May 19-June 15). Presenter: **Ghai S.**
- 2014 June 21 **Online Expert Consultant.** Follow-up after focal therapy in renal masses. Consensus project involving 3 rounds of questions according to the Delphi method, 3 days apart (May 5-June 10). Presenter: **Ghai S.**
- 2015 Mar 26 **Presenter.** Thyroid ultrasound and biopsy (workshop). Society of Abdominal Radiology (SAR) 2015 annual scientific meeting and educational course. San Diego, CA, USA. Presenter: **Ghai S.**
- 2015 Mar 24 **Workshop Co-Presenter.** Challenging image guided biopsies and role for image fusion and needle navigation. Society of Abdominal Radiology (SAR) 2015 annual scientific meeting and educational course. San Diego, CA, USA. Presenters: **Ghai S, Venkatesan AM.**
- 2014 Nov 14 **Invited Speaker.** MR guided focal therapy for prostate cancer. Annual Midland Urology Club, United Kingdom. Presenter: **Ghai S.**
- 2014 Nov 11 **Invited Speaker.** Which energy sources are feasible for focal therapy of PCa?. Targeted diagnosis and treatment in prostate cancer. Paracelsus Medical University, Salzburg, Austria. Presenter: **Ghai S.**
- 2014 Nov 11 **Invited Speaker.** Press conference on role of mpMRI in Cancer detection. Paracelsus Medical University, Salzburg, Austria. Presenter: **Ghai S.**
- 2014 Oct 15 **Panel Leader.** Controversies in Prostate Cancer Treatment panel. 4th International Symposium on Focused Ultrasound. Bethesda, MD, USA. Presenter: **Ghai S.**
- 2014 Aug 22 **Speaker.** Focal therapy (FT): energy modalities. 7th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. Los Angeles, CA, USA. Presenter: **Ghai S.**
- 2014 Aug 21 **Speaker.** Video session: intra-op focal therapy (FT) guidance. 7th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. Los Angeles, CA, USA. Presenter: **Ghai S.**
- 2014 Aug 21 **Moderator.** Poster session 1 (prostate). 7th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. Los Angeles, CA, USA. Presenter: **Ghai S.**
- 2014 Jul 21 **Online Expert Consultant.** Follow-up modalities after focal therapy for prostate cancer. University of Amsterdam, Academic Medical Center. Amsterdam, Netherlands. Consensus project involving 3 rounds of questions according to the Delphi method, 3 days apart (July 21-30). Presenter: **Ghai S.**

Sangeet GHAI

- 2014 May Magnetic resonance imaging detected prostate evasive anterior tumors: Further insights. American Urological Association. Orlando, FL, USA. Presenters: Al Edwan G, Marge! D, Haider M, **Ghai S**, Finelli A, Hamilton R, Kulkarni G, Toi A, Fleshner N.
- 2012 May Does the addition of apical injection of local anesthesia to basal injection diminish pain related to transrectal ultrasound guided prostate biopsy? American Urological Association annual meeting. Atlanta, GA, USA. Presenters: Toi A, Yang RA, Moshonov H, **Ghai S**, O'Malley ME, Margolis M, Sreeharsha B, Fleshner NE, Finelli A. Awarded "Best Poster".
- 2012 Jan 3 **Invited Speaker.** MR-guided focused ultrasound (MRgFUS): clinical research studies and applications in the abdomen. Sir Ganga Ram Hospital, New Delhi, India. Presenter: **Ghai S**.
- 2010 Nov Nonfocal renal biopsies: adequacy and factors affecting a successful outcome. Presentation at the 96th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: Goldstein MA, **Ghai S**, Atri M, O'Malley ME, Jacks L, Reich H, Herzenberg A.
- 2010 May Guide to hollow viscera surgical procedures. Educational exhibit presented at the 110th annual meeting of the American Roentgen Ray Society (ARRS). San Diego, CA, USA. Presenters: Roberts A, Fanous R, Jaffer NM, McLeod R, Chawla TP, Au WF, **Ghai S**.
- 2009 Nov Continuous ambulatory peritoneal dialysis: a guide to imaging features and their complications. Educational exhibit presented at the 95th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: Goldstein M, **Ghai S**, Hanbidge A.
- 2009 Apr Using reformatting algorithms for optimum thoracolumbar spine imaging. Electronic exhibit presented at the 109th annual meeting of the American Roentgen Ray Society (ARRS). Boston, MA, USA. Presenters: Merchant N, Jaffer N, **Ghai S**.
- 2009 Jan 6 **Invited Speaker.** Abdominal Imaging. AIIMS. New Delhi, India. Grand Rounds to Radiology Residents at AIIMS, New Delhi. Approximately 40 trainees attended.
- 2009 Jan 5 **Invited Speaker.** Liver transplant: CT evaluation. All India Institute of Medical Sciences. New Delhi, India. Presenter: **Ghai S**.
- 2008 Mar Laparoscopic nephrectomy: a radiologist's guide. Educational exhibit presented at the annual meeting of the European Congress of Radiology (ECR). Vienna, Niederösterreich, Austria. Presenters: Goldstein MA, Lapsia S, Golash A, **Ghai S**.
- 2007 Mar Gastrointestinal stromal tumours: imaging findings with histopathological correlation. Educational exhibit presented at the annual meeting of the European Congress of Radiology (ECR). Vienna, Niederösterreich, Austria. Presenters: Lapsia S, Ramachandra S, Smith V, **Ghai S**, Ghai S.
- 2005 Nov Primary gastrointestinal lymphoma: spectrum of imaging findings with pathological correlation. Educational exhibit presented at the 91st scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: **Ghai S**, Pattison J, Ghai S, O'Malley ME, Khalili K, Stephens M. Awarded "Certificate of Merit" and invited for submission to Radiographics.
- 2003 Dec Ultrasound imaging in uterine artery embolization patients: pre-procedure evaluation and post-procedure imaging findings. Educational exhibit presented at the 89th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: **Ghai S**, Rajan DK, Benjamin MS, Asch MR. Awarded "Certificate of Merit" and invited for submission to Radiographics.
- 2003 Dec MRI for hyperdense (>10HU) adrenal masses: does it still have a role? Presentation at the 89th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenter: **Ghai S**.

Sangeet GHAI

- 2003 Mar Efficacy of embolisation in traumatic uterine arterio-venous malformations. 28th annual meeting of the Society of Interventional Radiology (SIR). Salt Lake City, UT, USA. Presenter: **Ghai S.**
- 2001 Apr **Speaker.** Imaging in ophthalmology. Ophthalmic Panorama: Annual conference of Delhi Ophthalmological Society. New Delhi, India. Presenter: **Ghai S.**
- 2001 Mar Aortic aneurysm and dissection: evaluation with spiral CT angiography. Millennium Imaging Conference, All India Institute of Medical Sciences. New Delhi, India. Presenter: **Ghai S.**
- 2001 Mar Orbital histiocytosis. Educational exhibit presented at the Millennium Imaging Conference, All India Institute of Medical Sciences. New Delhi, India. Presenters: Vashisht S, **Ghai S**, Berry M.
- 2001 Mar Cystic lesions of the orbit. Educational exhibit presented at the Millennium Imaging Conference, All India Institute of Medical Sciences. New Delhi, India. Presenters: Vashisht S, **Ghai S**, Berry M.
- 2001 Mar Orbital pseudotumor. Educational exhibit presented at the Millennium Imaging Conference, All India Institute of Medical Sciences. New Delhi, India. Presenters: Vashisht S, Kapoor A, **Ghai S**, Berry M.
- 2001 Mar Tumors of the orbit. Educational exhibit presented at the Millennium Imaging Conference, All India Institute of Medical Sciences. New Delhi, India. Presenters: Vashisht S, **Ghai S**, Berry M.
- 2000 Dec **Speaker.** Imaging in pediatric nephrology. National Conference of Pediatric Nephrology, All India Institute of Medical Sciences. New Delhi, India. Presenter: **Ghai S.**
- 2000 Sep **Speaker.** Neuro ophthalmic imaging. Monthly meeting of Delhi Ophthalmological Society, RML Hospital. New Delhi, India. Presenter: **Ghai S.**

B) NATIONAL

- 2018 Apr 28 **Invited Faculty & Workshop Presenter.** Prostate MRI Workshop. Canadian Association of Radiology (CAR) Annual Scientific Meeting, Montréal, Québec.
- 2018 Apr 27 **Faculty.** Prostate MRI Workshop. 81st annual meeting of the Canadian Association of Radiologists (CAR). Montréal, Québec. Presenter: **Ghai S.**
- 2015 Oct 24 **Invited Speaker.** Recent advances in mp-MRI of the Prostate. Siemens Canada Innovations Symposium 2015. Presenter: **Ghai S.**
- 2012 Apr 27 **Invited Speaker.** MR-guided focused ultrasound (MRgFUS): overview of applications and clinical research studies. 75th annual meeting of the Canadian Association of Radiologists. Montréal, Québec. Presenter: **Ghai S.**

C) PROVINCIAL / REGIONAL

- 2017 Apr 8 **Invited Speaker.** Prostate MRI and MRI-TRUS fusion biopsy at the Juravinski Cancer Center Annual Uro-Oncology Forum, Pillar and Post, Niagara-on-the-Lake, Ontario.
- 2016 Sep 17 **Invited Speaker.** "Prostate MRI and TRUS fusion biopsy " at 8th Annual Princess Margaret Cancer Centre Uro-Oncology Dialogue held at Queens Landing, Niagara-on-the-Lake, Ontario. Presenter: **Ghai S.**
- 2014 Sep 21 **Speaker.** Focal ablation in prostate cancer. PMH Urology Dialogues meeting. Niagara-on-the-Lake, Ontario. Presenter: **Ghai S.**
- 2008 Nov 9 **Speaker.** Liver transplant assessment. Annual meeting of the Ontario Society of Diagnostic Medical Sonographers (OSDMS). Niagara-on-the-Lake, Ontario. Presenter: **Ghai S.**

D) LOCAL

- 2020 Sep 15 **Speaker.** Prostate Ultrasound and Biopsy. AIEC Canon Lecture Series. Presenter: **Ghai S.**
- 2019 Sept 20 **Speaker.** Prostate MRI. 34th annual Organ Imaging Review. Toronto, Ontario. Presenter: **Ghai S.**
- 2017 Oct 5 **Invited Speaker.** Localised Disease – Focal Therapy. Educational series preceptorship programs entitled: “*Present and Future of Prostate Cancer*”. Presenter: **Ghai S.**
- 2017 June 12 **Invited Speaker.** Prostate MRI. Annual Canadian Urological Association (CUA) meeting. Westin Harbor, Toronto, Ontario. Presenter: **Ghai S.**
- 2017 Feb 4 **Invited Speaker.** MRI in Prostate Imaging. Annual Medical Imaging and Alumni Day, Li Ka Shing Knowledge Institute, Toronto, Ontario. Presenter: **Ghai S.**
- 2016 Nov 17 **Invited Speaker.** Clinical applications of 29 MHz micro-ultrasound for targeted prostate biopsies. Innovations Toronto conference, Sunnybrook Health Sciences Centre, Toronto, Ontario. Presenter: **Ghai S.**
- 2016 Sept 30 **Invited Speaker.** In-bore Focal Laser Ablation for Prostate Cancer. 1st Toronto International Symposium for Focal Therapy in Prostate Cancer, Toronto, Ontario. Presenter: **Ghai S.**
- 2016 Sept 30 **Invited Speaker.** Lunch Symposium – Micro-ultrasound in Prostate Cancer detection. 1st Toronto International Symposium for Focal Therapy in Prostate Cancer, Toronto, Ontario. Presenter: **Ghai S.**
- 2016 Sept 30 **Invited Speaker.** ‘Should MRI be offered prior to initial biopsy’ 1st Toronto International Symposium for Focal Therapy in Prostate Cancer, Toronto, Ontario. Presenter: **Ghai S.**
- 2016 June 11 **Invited Speaker.** ‘Thyroid Ultrasound and Biopsy’ at the Toronto Head and Neck Imaging Course, at Li Ka Shing Knowledge Institute, Toronto, Ontario.
- 2015 Sep 27 **Speaker.** Prostate MRI. 30th annual Organ Imaging Review. Toronto, Ontario. Presenter: **Ghai S.**
- 2015 May 22 **Presenter.** Thyroid Ultrasound and Biopsy. Invited speaker at the ‘Interventional Radiology Lecture Series 2015’, The Hospital for Sick Children, Toronto, Ontario. Presenter: **Ghai S.**
- 2014 Nov 11 **Presenter.** Ultrasound imaging of the thyroid. Thyroid nodule/cancer management (tumor-board like format, specific questions before the meeting). Clinical Care Options (CCO) – Endocrine Community of Practice. Toronto, Ontario. Presenter: **Ghai S.**
- 2014 Oct 18 **Speaker.** MRI guided treatment of focal prostate cancer. 9th annual MRI Technologists’ Symposium. Toronto, Ontario. Presenter: **Ghai S.**
- 2014 Oct 8 **Speaker.** Prostate MRI. 29th annual Organ Imaging Review. Toronto, Ontario. Presenter: **Ghai S.**
- 2014 Jun 6 **Reviewer.** Tumour board panel. [Reviewed all images from panelists’ presentations of 4 cases.] International Sarcoma Symposium. Toronto, Ontario. Presenter: **Ghai S.**
- 2014 Jun 6 **Reviewer.** Parallel events: Tumour board for trainees: multi-disciplinary workshop. [Reviewed all images from workshop case presentations.] International Sarcoma Symposium. Toronto, Ontario. Presenter: **Ghai S.**
- 2014 Feb 24 **Speaker.** Imaging in retroperitoneal sarcomas. Academic half-day radiology seminar, Diagnostic Radiology Residency Program, University of Toronto. Toronto, Ontario. Presenter: **Ghai S.**
- 2014 Jan 18 **Speaker.** Thyroid biopsy: can we delegate? 4th annual Alumni Day, Department of Medical Imaging, University of Toronto. Toronto, Ontario. Presenter: **Ghai S.**
- 2013 Sep **Speaker.** Thyroid and parathyroid ultrasound. 28th annual Organ Imaging Review. Toronto, Ontario. Presenter: **Ghai S.**

Sangeet GHAI

- 2013 Jul 8 **Speaker.** CT Colonography [for Michener MRT students]. Michener CTC Day. Michener Institute. Toronto, Ontario. Presenter: **Ghai S.**
- 2012 Oct **Speaker.** Ultrasound-guided biopsies: tips, tricks, and other fine points. 27th annual Organ Imaging Review. Toronto, Ontario. Presenter: **Ghai S.**
- 2012 Jun **Invited Speaker.** UHN thyroid biopsy specialist program initiative. International Society of Radiographers and Radiological Technologists 70th annual meeting and 17th World Congress. Toronto, Ontario. Presenter: **Ghai S.**
- 2012 Apr 14 **Invited Speaker.** Evaluation of the UHN sonographer thyroid biopsy initiative. Spring Education Day, Ontario Society of Diagnostic Medical Sonographers (OSDMS). Toronto, Ontario. Presenter: **Ghai S.**
- 2012 Mar 10 **Invited Speaker.** MR-guided focused ultrasound (MRgFUS). Central section Education Day, Ontario Association of Medical Radiation Technologists (OAMRT). Toronto, Ontario. Presenter: **Ghai S.**
- 2011 Sep **Speaker.** Imaging in retroperitoneal masses. 26th annual Organ Imaging Review. Toronto, Ontario. Presenter: **Ghai S.**
- 2010 Oct 22 **Speaker.** The diagnosis of encapsulating peritoneal sclerosis: a radiologist's perspective. 2nd Peritoneal Grand Rounds on Encapsulating Peritoneal Sclerosis (EPS). Toronto, Ontario. Presenter: **Ghai S.**
- 2010 May 13 **Speaker.** Imaging for colon and rectal malignancy. General Surgery Lecture Series - Malignant Colon and Rectal Disease, Department of Surgery, University of Toronto. Toronto, Ontario. Presenter: **Ghai S.**
- 2008 Nov 21 **Speaker.** Radiation exposure in IBD patients and newer imaging techniques. Annual IBD update, Mount Sinai Hospital. Toronto, Ontario. Presenter: **Ghai S.**
- 2008 Sep **Speaker.** CT colonography: how to get started. 23rd annual Organ Imaging Review. Toronto, Ontario. Presenter: **Ghai S.**
- 2007 Feb **Speaker.** Primary gastrointestinal lymphomas: spectrum of imaging findings. Academic half-day radiology seminar, Diagnostic Radiology Residency Program, University of Toronto. Toronto, Ontario. Presenter: **Ghai S.**
- 2003 Jul Hyperdense adrenal nodules: is there still a role for dual-echo MRI? Educational exhibit presented at the 13th annual meeting of the International Society for Magnetic Resonance in Medicine (ISMRM). Toronto, Ontario. Presenters: **Ghai S**, Jhaveri KS, Haider MA.

Abstracts and Other Papers

- 2019 Oct Early Oncological and Functional Outcomes following MR guided Focal Laser Ablation (MRgFLA). Poster presentation at the 4th Global Summit on Precision Diagnosis and treatment of Pca. Boston, MA, USA.
- 2019 Oct Real time MR guided focused ultrasound for focal therapy of locally confined low-intermediate risk PCa: feasibility and preliminary outcomes. Poster presentation at the 4th Global Summit on Precision Diagnosis and treatment of Pca. Boston, MA, USA.
- 2018 Mar Evaluation of the Sonographic Features for Thyroid Nodules Biopsy Suggested by the 2015 American Thyroid Association Guidelines. Oral presentation at the 2018 AIUM Convention. New York, NY, USA.
- 2017 Mar A Comparison of Radiologists' and Urologists' Opinions Regarding Prostate MRI Reporting: A Survey of the Society of Abdominal Radiology Prostate Cancer Disease Focused Panel. Presentation at the annual scientific meeting and educational course at the Diplomat Resort & Spa. Hollywood, FL, USA

- (REB at UHN #16-5570). Presenters: Spilseth B, **Ghai S**, Patel NU, Taneja SS, Margolis DJ, Rosenkrantz AB.
- 2016 Nov Negative Predictive Value of Prostate Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated PSA: A Retrospective Cohort Study. Paper presentation at the 102nd scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: Burton K, Lo G, Haider MA, Finelli A, Fleshner NE, **Ghai S**.
- 2016 Nov Real time magnetic resonance guided focused ultrasound(MRgFUS) guided focal therapy of locally confined low-intermediate risk prostate cancer: Phase 1 study. Paper presentation at the 102nd scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: **Ghai S**, Lindner U, Eugen Hlasny, Haider MA, Kucharczyk W, Trachtenberg J.
- 2016 Nov Combining micro-ultrasound of the prostate, PRI-MUS™ protocol guidance along with patient screening profiles: Potential approach for reducing unnecessary biopsies. Scientific poster presentation at annual meeting of ESUI (EAU Section of Urologic Imaging). Milan, Italy. Presenters: Wodlinger B, **Ghai S**, Eure G, Fradet V, Hyndman ME, McGrath T, Pavlovich CP.
- 2016 Nov Using patient screening data and machine learning algorithms to improve PRI-MUS™ accuracy with micro-ultrasound based prostate biopsies. Scientific paper presentation at annual meeting of ESUI (EAU Section of Urologic Imaging) 2016, Milan, Italy. Presenters: **Ghai S**, Wodlinger B, Eure G, Fradet V, Hyndman ME, McGrath T, Pavlovich CP.
- 2015 Dec MRI evaluation of the prostate and predictors of local tumor recurrence following focal laser ablation. Poster presentation at the 101st scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: Barrett T, Haider MA, Trachtenberg J, **Ghai S**.
- 2015 Dec MRgFUS ablation of localized prostate cancer: Results of Phase 1 study. **Ghai S**, Perlis N, Finelli A, Fleshner, N. E, Kucharczyk W, Trachtenberg J. Poster presentation at the annual SUO meet, Baltimore, MD, USA.
- 2015 June In-bore focal laser ablation of prostate cancer: results of combined Phase I/II study. Poster presentation at the annual meeting of Canadian Urology Association. Montréal, Québec. Presenters: **Ghai S**, Finelli T, Lindner U, Davidson SRH, Hlasny E, McCluckey S, Kucharczyk W, Zlotta A, Trachtenberg J.
- 2015 June Magnetic resonance guided focused ultrasound for focal therapy of locally confined low risk prostate cancer: Results of Phase 1 study. Presenters: **Ghai S**, Louis AS, Van Vliet M, Lindner U, Haider MA, Hlasny E, Spensieri P, McCluskey S, Kucharczyk W, Trachtenberg J. Poster presentation at the 8th International Symposium on Focal Therapy and Imaging in prostate and kidney cancer, Amsterdam, Netherlands.
- 2015 June 10 Predicting underlying masses in appendiceal mucocoeles'. Oral Presentation at the annual meeting of the European Society of Abdominal Imaging (ESGAR), Paris, France. Presenters: Chaudhry S, McNaught R, Vajpeyi R, Chetty R, **Ghai S**.
- 2015 Mar Follow-up Modalities in Focal Therapy for Prostate Cancer: Results from a Delphi Consensus Project. Poster presentation at the 2015 annual meeting of the European Association of Urology (EAU). Madrid, Spain. Presenters: Muller BG, van den Bos W, Brausi M, Fütterer JJ, **Ghai S**, Pinto P, Popeneciu IV, de Reijke TM, Robertson C, de la Rosette JJMCH, Scionti S, Turkbey B, Wijkstra H, Ukimura O, Polascik TJ.
- 2014 Dec Real time MR imaging-guided in-bore focal laser ablation for low-to-intermediate risk prostate cancer: results of combined phase I/II study. Society of Urologic Oncology (SUO) 2014 winter meeting. Bethesda, MD, USA. Presenters: **Ghai S**, Lindner U, Haider M, Kucharczyk W, Barrett T, Trachtenberg J.

- 2014 Oct 14 Magnetic resonance guided focused ultrasound for focal therapy of locally confined low risk prostate cancer: preliminary outcomes. 4th International Symposium on Focused Ultrasound 2014. Bethesda, MD, USA. Presenter: **Ghai S**.
- 2014 Sep Fine needle biopsies are feasible as a minimally invasive means for targeted next generation sequencing in advanced solid tumors. Poster presentation at the European Society for Medical Oncology (ESMO) 2014 Congress. Madrid, Spain. Presenters: Hansen A, Geddie W, Boerner S, **Ghai S**, Berman H, Serra S, Roehrl M, Joshua AM, Oza AM, Moore M, Amir E, Usmani T, Giesler A, Amin N, Zhang T, Sukhai M, Stockley T, Kamel-Reid S, Siu LL, Bedard P. Translational research.
- 2013 Dec Multimodality approach to primary cystic peritoneal masses and intraabdominal cystic mimickers: what every radiologist should know. Educational exhibit presented at the 99th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: Arraiza M, Metser U, Vajpeyi RK, Kennedy E, **Ghai S**. Awarded Certificate of Merit.
- 2013 Dec Combined results of phase I/II trial of MR imaging-guided focal laser ablation for low-to-intermediate risk prostate cancer: a move from active to 'proactive' surveillance. Educational exhibit presented at the 99th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: Barrett T, **Ghai S**, Davidson SRH, Hlasny E, Cepek J, Trachtenberg J, Haider MA.
- 2013 May Feasibility study to evaluate the safety and preliminary effectiveness of focal MRgFUS surgery of locally confined low-risk prostate cancer: the initial North American experience on four patients. 6th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. Noordwijk, Netherlands. Presenters: **Ghai S**, Louis AS, Lindner U, Haider M, Kucharczyk W, McCluskey S, van der Kwast T, Trachtenberg J.
- 2013 May "Dynamic" active surveillance; a new strategy to follow patients with low and intermediate risk prostate cancer: combined results of an expanded phase I/II trial of MR imaging-guided focal laser ablation for low-to-intermediate risk prostate cancer. 6th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. Noordwijk, Netherlands. Presenters: **Ghai S**, Barrett T, Lindner U, Haider MA, Davidson S, Cepek J, Hlasny E, Gertner M, Trachtenberg J.
- 2013 May MRI-guided focal laser ablation of prostate cancer using a mechatronic needle guidance system: experience in seven patients. 6th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. Noordwijk, Netherlands. Presenters: Cepek J, Lindner U, **Ghai S**, Haider MA, Davidson SRH, Hlasny E, Trachtenberg J, Kucharczyk W, Fenster A.
- 2013 May Guidance software for MR-guided focal laser thermal therapy of prostate cancer. 6th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. Noordwijk, Netherlands. Presenters: Davidson SRH, Lindner U, Cepek J, Sussman M, Haider MA, **Ghai S**, Fenster A, Trachtenberg J.
- 2013 Apr Initial experience with MR guided focused ultrasound therapy of prostate cancer. Poster presentation at the annual meeting of the International Society for Magnetic Resonance in Medicine (ISMRM)/Section for Magnetic Resonance Technologists (SMRT). Salt Lake City, UT, USA. Presenters: Hlasny E, **Ghai S**, Lindner U, Sussman SM, Spiller N, Spensieri P, Trachtenberg J, Kucharczyk W, McCluskey S.
- 2013 Mar A practical approach to cystic peritoneal masses and neoplasms: pearls and tips. Annual meeting of European Congress of Radiology (ECR). Vienna, Austria. Presenters: Arraiza Sarasa M, **Ghai S**, Metser U, Kennedy E, Vajpeyi R. Educational exhibit.
- 2012 Dec UHN thyroid biopsy specialists program: an innovative role for the radiology assistant. Quality storyboard exhibit presented at the 98th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenter: **Ghai S**.
- 2012 Oct 16 Feasibility study to evaluate the safety and preliminary effectiveness of focal MR-guided focussed ultrasound surgery (MRgFUS) for locally confined low-risk prostate cancer: the first North American

- experience. Oral presentation at the 3rd International Symposium on Focused Ultrasound. Bethesda, MD, USA. Presenters: **Ghai S**, Lindner U, Haider M, Kucharczyk W, McCluskey S, van der Kwast T, Trachtenberg J.
- 2012 Jun Imaging in retroperitoneal tumors. Educational exhibit presented at the European Society of Gastrointestinal and Abdominal Radiologists (ESGAR) 23rd annual meeting. Edinburgh, United Kingdom. Presenters: **Ghai S**, Brennan C.
- 2012 May Does the addition of apical injection of local anesthesia to basal injection diminish pain related to transrectal ultrasound guided prostate biopsy? Poster presentation at the annual meeting of the American Urological Association. Atlanta, GA, USA. Presenters: Toi A, Yang RA, Moshonov H, **Ghai S**, O'Malley ME, Margolis M, Sreeharsha B, Fleshner NE, Finelli A. Awarded "Best Poster".
- 2010 Nov Nonfocal renal biopsies: adequacy and factors affecting a successful outcome. Presentation at the 96th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: Goldstein MA, **Ghai S**, Atri M, O'Malley ME, Jacks L, Reich H, Herzenberg A.
- 2010 May Guide to hollow viscera surgical procedures. Educational exhibit presented at the 110th annual meeting of the American Roentgen Ray Society (ARRS). San Diego, CA, USA. Presenters: Roberts A, Fanous R, Jaffer NM, McLeod R, Chawla TP, Au WF, **Ghai S**.
- 2009 Nov Continuous ambulatory peritoneal dialysis: a guide to imaging features and their complications. Educational exhibit presented at the 95th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: Goldstein M, **Ghai S**, Hanbidge A.
- 2009 Apr Using reformatting algorithms for optimum thoracolumbar spine imaging. Electronic exhibit presented at the 109th annual meeting of the American Roentgen Ray Society (ARRS). Boston, MA, USA. Presenters: Merchant N, Jaffer N, **Ghai S**.
- 2009 Jan 6 **Invited Speaker**. Abdominal Imaging. AIIMS. New Delhi, India. Grand Rounds to Radiology Residents at AIIMS, New Delhi. Approximately 40 trainees attended. Presenter: **Ghai S**.
- 2009 Jan 5 **Invited Speaker**. Liver transplant: CT evaluation. All India Institute of Medical Sciences. New Delhi, India. Presenter: **Ghai S**.
- 2008 Mar Laparoscopic nephrectomy: a radiologist's guide. Educational exhibit presented at the annual meeting of the European Congress of Radiology (ECR). Vienna, Niederösterreich, Austria. Presenters: Goldstein MA, Lapsia S, Golash A, **Ghai S**.
- 2007 Mar Gastrointestinal stromal tumours: imaging findings with histopathological correlation. Educational exhibit presented at the annual meeting of the European Congress of Radiology (ECR). Vienna, Niederösterreich, Austria. Presenters: Lapsia S, Ramachandra S, Smith V, **Ghai S**, Ghai S.
- 2005 Nov Primary gastrointestinal lymphoma: spectrum of imaging findings with pathological correlation. Educational exhibit presented at the 91st scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: **Ghai S**, Pattison J, Ghai S, O'Malley ME, Khalili K, Stephens M. Awarded "Certificate of Merit" and invited for submission to Radiographics.
- 2003 Dec Ultrasound imaging in uterine artery embolization patients: pre-procedure evaluation and post-procedure imaging findings. Educational exhibit presented at the 89th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenters: **Ghai S**, Rajan DK, Benjamin MS, Asch MR. Awarded "Certificate of Merit" and invited for submission to Radiographics.
- 2003 Dec MRI for hyperdense (>10HU) adrenal masses: does it still have a role? Presentation at the 89th scientific assembly and annual meeting of the Radiological Society of North America (RSNA). Chicago, IL, USA. Presenter: **Ghai S**.

Sangeet GHAI

- 2003 Jul Hyperdense adrenal nodules: is there still a role for dual-echo MRI? Educational exhibit presented at the 13th annual meeting of the International Society for Magnetic Resonance in Medicine (ISMRM). Toronto, Ontario, Canada. Presenters: **Ghai S**, Jhaveri KS, Haider MA.
- 2003 Mar Efficacy of embolisation in traumatic uterine arterio-venous malformations. 28th annual meeting of the Society of Interventional Radiology (SIR). Salt Lake City, UT, USA. Presenter: **Ghai S**.
- 2001 Apr **Speaker**. Imaging in ophthalmology. Ophthalmic Panorama: Annual conference of Delhi Ophthalmological Society. New Delhi, India. Presenter: **Ghai S**.
- 2001 Mar Aortic aneurysm and dissection: evaluation with spiral CT angiography. Millennium Imaging Conference, All India Institute of Medical Sciences. New Delhi, India. Presenter: **Ghai S**.
- 2001 Mar Orbital histiocytosis. Educational exhibit presented at the Millennium Imaging Conference, All India Institute of Medical Sciences. New Delhi, India. Presenters: Vashisht S, **Ghai S**, Berry M.
- 2001 Mar Cystic lesions of the orbit. Educational exhibit presented at the Millennium Imaging Conference, All India Institute of Medical Sciences. New Delhi, India. Presenters: Vashisht S, **Ghai S**, Berry M.
- 2001 Mar Orbital pseudotumor. Educational exhibit presented at the Millennium Imaging Conference, All India Institute of Medical Sciences. New Delhi, India. Presenters: Vashisht S, Kapoor A, **Ghai S**, Berry M.
- 2001 Mar Tumors of the orbit. Educational exhibit presented at the Millennium Imaging Conference, All India Institute of Medical Sciences. New Delhi, India. Presenters: Vashisht S, **Ghai S**, Berry M.
- 2000 Dec **Speaker**. Imaging in pediatric nephrology. National Conference of Pediatric Nephrology, All India Institute of Medical Sciences. New Delhi, India. Presenter: **Ghai S**.
- 2000 Sep **Speaker**. Neuro ophthalmic imaging. Monthly meeting of Delhi Ophthalmological Society, RML Hospital. New Delhi, India. Presenter: **Ghai S**.

CE Course

- 2021 Oct 16 **Course Director**. Prostate MRI Workshop [Online]
- 2019 Mar 26 **Course director**. Focal Therapy in Localized Prostate Cancer. 2019 Society of Interventional Radiology (SIR) Annual Scientific Meeting. Austin, TX, USA. Presenter: **Ghai S**.
- 2016 Oct 1 **Course Director**. Prostate MRI Workshop. Hyatt Regency, Toronto, Ontario. Presenter: **Ghai S**.
- 2016 Sept 30 **Course Director**. 1st Toronto International Symposium for Focal Therapy in Prostate Cancer. Toronto, Ontario. Presenter: **Ghai S**.
- 2014 Oct 16 **Co-Director**. Interactive Renal Transplant Imaging and Biopsy. University of Toronto/Michener Institute. Toronto, Ontario. Presenter: **Ghai S**.
- 2015 May 29 **Course Director**. Prostate MRI Workshop. University of Toronto AIEC. Toronto, Ontario. Accredited for for 4.5 hours learning under Section 1 and 4.5 hours learning under Section III, as defined by the MoC Program of the Royal College of Physicians and Surgeons of Canada. Presenter: **Ghai S**.